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ABSTRACT 
 
 
Spectinamides are novel amide derivatives of the antibiotic spectinomycin that 
have emerged as a new class of agents to treat tuberculosis. These agents showed potent 
in vitro activity against Mycobacterium tuberculosis (MTB) compared to spectinomycin 
and in a preliminary in vivo study in interferon gamma (IFN-γ) knockout mice, 
spectinamide Lee1329 reduced the lung bacillary load of TB comparable to streptomycin. 
We hypothesized that the application of an iterative pharmacokinetics and 
pharmacodynamics (PK/PD) guided approach would facilitate the optimization of these 
lead compounds suitable for further development.  
 
A series of in vitro experiments including parallel artificial membrane 
permeability assay (PAMPA), microsomal metabolic stability using rat liver microsomes 
and protein binding assay were designed to characterize the in vivo biopharmaceutic and 
pharmacokinetic behavior. Drug uptake studies into Mycobacterium bovis BCG and into 
J774 murine macrophages were performed to understand reasons for improved activity of 
spectinamides and to evaluate their potential to target primary TB infection that resides in 
macrophages. In vivo pharmacokinetic studies were carried out in rats by intravenous (10 
mg/Kg) and oral administration (100 mg/Kg) of the compounds. LC-MS/MS assays were 
developed to quantify concentrations in test samples obtained from these studies.  
 
Spectinamides exhibit low to intermediate plasma protein binding and were found 
to be metabolically stable. Following intravenous administration, spectinamides were 
relatively widely distributed (0.36 to 1.15 L/Kg) with short half-lives (0.43 to 0.62 hr). 
Mean systemic clearance ranged between 0.36 and 0.89 L/hr/Kg with a significant 
fraction of drug eliminated unchanged in urine (0.46 to 1.0). Spectinamides exhibited a 
renal excretion ratio greater than one indicating filtration and active secretion as the net 
renal elimination process. In the uptake experiments, the spectinamides exhibited 3-4 
times higher uptake into murine macrophages compared to streptomycin and showed 
nearly four times higher uptake into M. bovis BCG compared to spectinomycin, which 
may in part explain their increased activity compared to spectinomycin. 
 
In a previously reported in vitro PK/PD system, PK concentration-time profiles 
were simulated on the basis of the in vivo clearance of rats obtained from the PK studies 
and different daily doses of 0.4, 2, 10 and 50 mg/Kg/day of Lee1445 were added as QD, 
BID or TID regimens. The time-kill effect of these regimens was studied on the growing 
M. bovis BCG present in the system. A semi-mechanistic model incorporating a logistic 
function for growth of mycobacteria in the absence of drug and an inhibitory sigmoidal 
Emax model with a delay function for the time-kill effect of the drug was fit to the data 
and the in vitro PK/PD parameters were determined. Since the in vivo efficacy model of 
tuberculosis infection was the gamma knock-out (GKO) mice, a PK bridging study was 
performed in mice following intraperitoneal administration of 20 mg/Kg Lee1445. 
Simulations for various dosing regimens were performed using the obtained mouse PK 
parameters and the in vitro PK/PD parameters that were incorporated into a combined 
PK/PD model to predict the efficacy in terms of reduction of bacterial counts measured in 
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log CFU/mL. Based on the results of the simulations, an optimal dose was chosen for the 
in vivo efficacy study.  
 
The results from the in vitro PK/PD studies showed that QD was marginally 
effective. The same total daily dose administered BID showed a marked reduction in 
mycobacterial counts. TID dosing did not show a significant difference in time-kill 
compared to BID regimen. The maximum growth rate constant (K0) was estimated as 
0.0274 hr-1 which corresponds to a maximum doubling time of 25.3 hr that is consistent 
with the commonly observed in vitro doubling times of 20-24 hr. A maximum bacterial 
kill rate (Imax) was calculated as 0.0566 hr-1. The free drug concentration required to 
produce half-maximum inhibition (IC50) was calculated as 2.62 mg/L. The delay rate 
constant for the initial kill was found to be 0.0245 hr-1. The PK bridging study showed 
that the Lee1445 half-life was shorter in mice (0.25 hr) compared to rats (0.43 hr). 
Simulations based on the parameters obtained from the mouse PK bridging study and the 
in vitro PK/PD model suggested that a total daily dose of 200 mg/Kg/day and 400 
mg/Kg/day administered BID would be optimal and result in approximately 2 and 3 log 
reduction in bacterial counts respectively after seven days of therapy and hence were 
chosen for in vivo efficacy studies in mice.    
 
In summary, we have successfully developed a series of biopharmaceutic, PK and 
PD experiments that help in an iterative PK/PD guided approach for development of 
spectinamides, a novel class of antituberculosis agents. The in vivo PK and in vitro 
PK/PD parameters obtained from these studies provide a basis for optimal compound as 
well as dose selection.  
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CHAPTER 1. BACKGROUND* 
 
 
Tuberculosis and Drug Development 
 
According to the World Health Organization (WHO) report on global tuberculosis 
control 2010, the incidence of tuberculosis (TB) cases was 9.4 million in 2009. There are 
half a million cases of multidrug resistant TB (MDR-TB) with approximately 58 
countries and territories reporting at least one case of extensively drug resistant TB 
(XDR-TB) (1).  
 
Currently used treatment strategies involve multiple drugs with treatment periods 
ranging from 6 months up to 2 years. MDR-TB patients in particular undergo treatment 
with more toxic and expensive drugs with poor patient compliance. Hence there is a 
definite need for more effective and better tolerated antituberculosis agents to go into 
optimized, less complicated and shorter dosage regimens. The path to new antibiotic drug 
discovery and development is a long and expensive process with very few compounds 
making it to the market. Development of antituberculosis drugs in particular was halted 
during the last decades of the 20th century due to a lack of commercial incentive, which 
has only recently been addressed after a hiatus of almost 40 years through extensive 
governmental and non-governmental organizational and financial support.  
  
In recent years the U.S. Food and Drug Administration (FDA) has suggested 
numerous approaches to optimize the drug development process. 
Pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation is one such 
innovative tool intended to help in early go or no-go decisions and significantly 
improving development efficiency. For example, in preclinical as well as clinical 
development, PK/PD modeling and simulation can be used to integrate independent 
measures of potency, safety, bioavailability, and clearance including their inter-individual 
variability and measurement uncertainty to develop optimal dosing regimens with regard 
to safety and efficacy, and to explore different treatment algorithms and trial designs with 
regard to their likelihood of being successful (2-4).  
 
There is often only limited PK/PD information available for molecules under 
development because of a lack of inexpensive suitable animal models to predict efficacy, 
a poor understanding of the relationship between PK and PD for novel compounds, and 
challenges by complex disease processes, such as the phenomena of latency and drug 
tolerance in TB infections (5). Hence, improved tools are needed to evaluate the PK and 
PD properties and optimize dosing regimens for drug candidates early in the development 
process. 
 
 
 
* This chapter adapted with permission. P.K. Vaddady, R.E. Lee, and B. Meibohm. In 
vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: 
Focus on TB. Future Med Chem., 2:1355-1369 (2010). 
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Pharmacokinetic/Pharmacodynamic Parameters of Antituberculosis Agents 
 
 
Pharmacokinetics 
 
Pharmacokinetics describes the time course of concentration of a drug resulting 
from administration of a dosage regimen and accounts for its absorption, distribution, 
metabolism and excretion in the body. From a biopharmaceutic and pharmacokinetic 
standpoint, an ideal TB drug should possess good metabolic stability and high oral 
bioavailability, since oral administration is the route of choice for better patient 
compliance, indicating that the compound should have good aqueous solubility and 
gastrointestinal permeability. In order to allow lesser frequency of dosing, it should 
possess longer elimination half-life (5). To target the primary phase of TB infection, the 
drug should be able to penetrate into macrophages and also into the bacterial envelope 
assuming the drug target is located intracellularly. 
 
Metabolic Stability 
 
Drugs are most often eliminated in the liver via biotransformation and/or 
excretion into urine or bile. Along with xenobiotic transformation, liver plays a very 
important role in characterizing the metabolic stability, drug-drug interaction potential, 
and toxicity of drugs (6, 7). Two major enzyme systems Phase I and Phase II are 
responsible for biotransformation in the liver. Phase I reactions include oxidation, 
reduction and/or hydrolysis many of which are catalyzed by the cytochrome P450 (CYP) 
family of enzymes present in the smooth endoplasmic reticulum and require NADPH as a 
cofactor. Phase II enzymes present in the cytoplasm and endoplasmic reticulum are 
responsible for inactivating the drug via conjugation reactions with glucuronic acid, 
sulphate, glutathione and glutamine where they render the conjugate water soluble 
leading to its elimination. Sub cellular fractions of liver tissue known as microsomes are 
membrane vesicles of the smooth endoplasmic reticulum containing the CYP enzymes 
which can be used to assess the susceptibility of drug candidates to solely metabolism by 
CYP enzymes. Metabolic stability of a compound is investigated using such microsomes 
to determine metabolic half-life and intrinsic clearance which can be major determinants 
for in vivo hepatic clearance which further governs the pharmacokinetic properties such 
as first-pass elimination of the drug  and there by oral bioavailability, systemic 
elimination and the half-life (8, 9).  
  
Protein Binding 
 
Free or unbound drug concentrations are of therapeutic interest because they are 
relevant for the pharmacological effect of a drug as well as its metabolism and excretion. 
Therefore it is important to estimate the extent of protein binding. Drugs are classified as 
highly bound if the free fraction in plasma (fup) ≤ 0.1, moderately protein bound if 0.1 ≤ 
fup ≤ 0.4 and low protein bound if fup ≥ 0.4. Using the total instead of free drug 
concentrations becomes valid as long as the degree of binding and thus the ratio of free to 
total drug concentration remain constant. However if this ratio changes due to disease 
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states or drug-drug interactions then it is important to note that the total drug 
concentration does not provide a valid substitute for free drug concentration. For drugs 
with low protein binding, protein binding modifications due to pathophysiological 
conditions or drug-drug interactions is not considered clinically relevant.  
  
Bioavailability 
 
Bioavailability is defined as rate and extent to which a drug is absorbed and 
becomes available in the systemic circulation. The three important components namely 
fraction absorbed from the gastrointestinal tract, fraction escaping the gut wall 
metabolism and the fraction escaping the first pass-metabolism contribute to the oral 
bioavailability. Physicochemical properties such as solubility, lipophilicity, charge state 
(extent of ionization) and stability, and physiological conditions such as gastric emptying 
time, intestinal transit time and gastrointestinal pH influence the absorption of drug 
molecules across the gastrointestinal mucosa (5).  
 
Optimizing the chemical structure to improve one or more of these properties 
during the early discovery and development stage has been one of the approaches to 
improve oral bioavailability. Prodrug strategies have also been successfully implemented 
to improve the oral bioavailability of numerous compounds. In many cases, this involves 
masking a polar group by esterification to increase lipophilicity and enhance the extent of 
absorption from the gastrointestinal tract. After absorption, the ester is enzymatically 
hydrolyzed to release the parent drug (10).   
 
Drug Uptake into Macrophages and Mycobacteria 
 
MTB is a highly successful pathogen that parasitizes macrophages of the host by 
manipulating the phagosome that it resides in and prevents the normal maturation of this 
organelle into an acidic, hydrolytic compartment (11). A beneficial consequence of the 
accumulation of a drug within such host cells as macrophages is its increased activity 
against intracellular pathogens and therefore evaluating the drug uptake into macrophages 
plays an important role in the early drug development especially for antituberculosis 
agents. Also by comparing the uptake of drugs, which do not possess any antituberculosis 
activity, into mycobacteria against those that are active, helps in the answering the 
fundamental mechanisms by which these compounds find their way across the 
prokaryotic cell envelope to their ribosomal targets.  
 
 
Pharmacodynamics 
 
Pharmacodynamics describes the intensity of drug effect in relation to its 
concentration. In the context of anti-infective therapy, pharmacodynamics defines the 
effect of drug on the pathogen residing in the host organism. In order to quantify the 
antituberculosis activity of drugs against the infectious pathogen, minimum inhibitory 
concentration (MIC) and minimum bactericidal concentration (MBC) are most 
commonly used parameters to date.  
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MIC is defined as the lowest concentration that prevents growth of bacteria within 
a defined time period of incubation, typically around seven days for Mycobacterium 
tuberculosis (MTB) with a standard inoculum (~105 colony forming units (CFU)/mL) 
(12). MBC is defined as the drug concentration that produces 99.99% killing of bacterial 
cells in the initial inoculum. Although MIC and MBC seem to be good measures of the 
potency of a drug and its interaction with a pathogen, they do not provide any 
information on the time course of the antimicrobial activity. 
 
PK/PD indices are composites of a pharmacokinetic parameter such as area under 
the plasma concentration-time curve (AUC) or maximum plasma concentration (Cmax) 
and a microbiological parameter such as minimum inhibitory concentration (MIC). Most 
frequently used PK/PD indices of antibiotics based on MIC, shown in Figure 1-1, are 
time above MIC (T >MIC), ratio of peak concentration to MIC (Cmax/MIC), ratio of area 
under the curve (AUC) to MIC (AUC/MIC) and area under the inhibitory curve (AUIC), 
which is calculated as the area under the curve where the plasma concentration exceeds 
MIC (AUCT >MIC/MIC). If drug concentrations remain above MIC at all times, then AUIC 
and AUC/MIC are identical (13).  
 
The most common approach to antibiotic dosing is to adjust the doses to obtain 
antibiotic plasma concentrations that are above the MIC or a multiple thereof for a given 
pathogen throughout the dosing interval. Two distinct groups can be differentiated on the 
basis of the pattern of antimicrobial activity. The first pattern is characterized by 
concentration-dependent killing over a wide range of concentrations, where higher 
concentrations lead to a greater rate and extent of killing. Intracellularly acting drugs such 
as aminoglycosides, rifamycins and fluoroquinolones fall under this pattern.  The second 
group involves time-dependent killing, where the time of exposure governs the 
bactericidal activity. Antibiotics that act on cell wall targets such as penicillins and 
cephalosporins exhibit such killing pattern (14).  
 
AUC/MIC and Cmax/MIC explain the bactericidal activity of concentration 
dependent killing while T>MIC explains the time-dependent killing pattern. Table 1-1 
provides a compilation of the PK/PD indices and related PK parameters of existing 
antituberculosis drugs. It should be noted that, with the exception of the first-line agents 
for which some dose optimization in the TB indication has been performed, the 
calculated PK/PD parameters indicated in the table may not necessarily be the most 
optimal for driving efficacy in TB patients. 
 
 
 Spectinomycin 
 
Spectinomycin (SPC) is a broad-spectrum antibiotic that selectively targets 
bacterial ribosomes and remains important in both clinical and veterinary use (15). It was 
first isolated in 1960 from the fermentation broth of Streptomyces spectabilis, a soil 
microorganism, by Upjohn research laboratory (16, 17).  
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Figure 1-1. Commonly used pharmacokinetic/pharmacodynamic indices. 
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Table 1-1. Reported PK/PD parameters of antituberculosis drugs (5, 18-27). 
  
Use Class Name Dose range Half-life (hr) fup Cmax/MIC AUC/MIC T>MIC 
First-line Oral agents Rifampin 8-12 mg/Kg 2-5 0.1 24 39.9 9 
  Isoniazid 4-6 mg/Kg 2-4.5 (slow) 0.99 40 19.2 18   0.75-1.8 (fast) 11.6 9 
  Pyrazinamide 20-30 mg/Kg 10-24 0.9 3.8 52 na 
  Ethambutol 15-20 mg/Kg 3-4 0.7 10 23.4 13 
 Injectables Streptomycin 12-18 mg/Kg 2-4 0.45 10 124.5 8 
         
Second-line Fluoroquinolones Moxifloxacin 400 mg 12-14 0.5 12.3 110.5 na 
  Gatifloxacin 400 mg 7-14 0.8 9.5 85.6 na 
  Ciprofloxacin 750 mg 4 0.6 5 16.9 10.5 
  Ofloxacin 1000 mg 3-7 0.7 5 47.4 15.5 
 Injectables Amikacin 15 mg/Kg 2-3 0.9 43 na na 
  Kanamycin 15-30 mg/Kg 2.5 0.99 20 na na 
  Capreomycin 15-30 mg/Kg 4-6 na 20 na na 
 Oral bacteriostatics Ethionamide 15-20 mg/Kg 2-3 0.7 1.6 1 1.5 
  Cycloserine 15-20 mg/Kg 10 na 3.8 195.5 22.5 
  PASA 150 mg/Kg 2-3 0.85 75 153.7 4 
  Thiacetazone 150 mg 4 0.05 1.3 1.2 5.5 
 Others Linezolid 600 mg 4.5-5.5 0.7 20 107.8 na 
 
Notes:  PASA: Para-amino salicylic acid 
fup: Fraction of unbound drug in plasma  
Cmax/MIC: Ratio of peak serum concentration to minimum inhibitory concentration 
AUC/MIC: Ratio of area under plasma concentration-time curve to MIC 
T>MIC: Percentage of time during which the serum concentration remains above the MIC 
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Mechanism of Action and Indications 
 
SPC is an aminocyclitol antibiotic resembling kanamycin and gentamicin but is 
not an aminoglycoside (28-30). It binds to the 30S ribosomal subunit of the 
microorganism and inhibits protein synthesis by interfering with peptidyl tRNA 
translocation and preventing elongation of the polypeptide chain at the translocation step 
(31). It sterically blocks the swiveling of the head domain of the small ribosomal subunit 
and thereby disrupts the translocation cycle (15).  
  
Although it is active in vitro against a variety of aerobic gram-negative and gram-
positive bacteria, its primary clinical use has been in the treatment of uncomplicated 
infections with Neisseria gonorrhoeae. SPC is bactericidal against this pathogen, and 
most strains of gonococci are inhibited by 6.3 µg/mL or less of SPC with a range of 2 to 
20 µg/mL (32). Trobicin® (spectinomycin dihydrochloride pentahydrate) was first 
approved by Food and Drug Administration in 1971 for indications limited to acute 
gonococcal urethritis and proctitis in men and acute gonococcal cervicitis and proctitis in 
women (28). In veterinary medicine, it is used in many indications such as chronic 
respiratory disease, colibacillosis, paratyphoid, synovitis, and salmonella infections in 
chicken, bacterial enteritis in pigs and bacterial pneumonia in cattle (33). 
 
 
Preclinical and Veterinary Pharmacokinetics 
 
Absorption 
 
SPC is rapidly absorbed following intramuscular (i.m.) administration. Following 
single i.m. administration of 50 mg/Kg in chicken, Cmax was found to be 152.8 µg/mL 
achieved at 0.25 hr. SPC was completely bioavailable following i.m. administration with  
absolute bioavailability (Fabs) values of 136% in chicken, 118% in cattle and 104% in 
sheep. Subcutaneous (s.c.) administration of 50 mg/Kg in chicken produced a Cmax of 
99.8 µg/mL and Fabs of 128%. However, following oral administration of 50 mg/Kg and 
100 mg/Kg in chicken, Fabs was found to be 11.8 and 26.4% with Cmax values of 5.13 and 
14.26 µg/mL respectively, indicating that SPC is poorly absorbed from the 
gastrointestinal tract (33-35). Repeated administration in cattle did not result in higher 
tissue concentration than those achieved via single dose (33, 36). 
 
Distribution 
 
After a single intravenous (i.v.) administration of 50 mg/Kg in chicken, the 
volume of distribution of SPC based on the terminal phase (Vz) was 0.34 L/Kg 
suggesting that the distribution of the drug is limited to extracellular fluid. Similar values 
have been reported for cow (0.3 L/Kg) and sheep (0.3 L/Kg) (34, 37). Twelve hours 
following i.m. administration and 24 hours following oral administration, concentrations 
have been found in the following swine tissues in decreasing order: kidney, liver, lung, 
muscle and fat. A similar profile has been observed in cattle following i.m. administration 
after 24 and 72 hours. Tissue/serum ratios did not exceed 0.5 and were found to be much 
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lower in brain, aqueous humor and bone (38). Protein binding was found to be low (10%) 
in cows (37). 
 
Metabolism and Excretion 
 
SPC does not appear to undergo any significant metabolism. In swine it was 
found to be excreted unchanged in the urine following i.m. administration. Following 
single dose i.m. administration, the overall elimination half-life (t1/2β) of SPC was 
comparable across species with cattle (1.2 hr), sheep (1.1 hr), pigs (0.98 hr) and chicken 
(1.65 hr) respectively. This short elimination half-life suggests that SPC is eliminated 
rapidly from the body and supports the fact that a majority of it is excreted unchanged in 
the urine (34, 36, 37, 39). 
 
SPC is rapidly absorbed and quickly eliminated from plasma as well as tissues via 
urinary elimination. This explains the reason for no accumulation following repeated 
doses in cattle. Since a majority of this drug is renally eliminated it is important to note 
that accumulation can occur in renally impaired animals. Following oral administration 
SPC is excreted mostly in the feces as it is poorly absorbed from the gastrointestinal tract. 
Total clearance in chicken has been reported as 2.68 mL/min/Kg following i.m. 
administration (33, 34, 36, 38). 
 
 
Human Pharmacokinetics 
 
Absorption 
 
SPC is not significantly absorbed from the gastrointestinal tract but is well 
absorbed when given via the intramuscular route. Following a 0.5 g dose via i.m. 
injection, the absorption rate constant was found to be 1.48 hr-1 corresponding to an 
absorption half-life of 0.47 hr. Following a single two-gram i.m. injection, peak serum 
concentrations average 100 µg/mL at one hour, while a single four-gram injection 
produces peak serum concentration averaging 160 µg/mL at two hours. Average serum 
concentrations of 15 µg/mL for the two-gram dose and 31 µg/mL for the four-gram dose 
were present eight hours after dosing (40-42). In children, serum concentrations ranged 
from 22 to 87.5 µg/mL following 40 mg/Kg i.m. administration (43). 
 
Distribution 
 
SPC when administered via i.v., i.m. or constant rate i.v. infusion shows a bi-
exponential disposition with a volume of central compartment about twice the volume of 
the peripheral compartment. The average total volume of distribution was 11.5 L. The 
average inter-compartmental distribution rate constant was found to be approximately 0.5 
hr-1. SPC has minimal protein binding (42). Tissue distribution studies performed in 
uterus and fallopian tube suggested that tissue levels of SPC were about one-third to one-
quarter the levels in the serum (40).  
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Metabolism and Excretion 
 
SPC does not undergo significant metabolism. It is largely eliminated by renal 
excretion. The first order elimination rate constant following a single dose 0.5 g i.m. 
administration was 0.694 hr-1 corresponding to a half-life of about 1 hr. Following i.v. 
and i.m. administration approximately 75% of the drug was excreted unchanged in the 
urine (42). The pharmacokinetics of SPC after 2 g i.v. injection studied in volunteers with 
varying degrees of renal function showed similar mean peak concentrations as compared 
to individuals with normal renal function but the half-lives ranged from 4.7 to 29.3 hr 
(44). Since SPC is minimally bound to plasma proteins, the antibiotic may be excreted 
entirely by glomerular filtration and hence changes in renal function can significantly 
impact the clearance of the drug.  
 
 
Toxicity 
 
SPC is well tolerated when administered as single i.v. or i.m. injection. In 
animals, i.m. injection of large doses of SPC for 90 days produced only low-grade 
histopathologic changes at the injection sites (45). It does not show cross-allergenicity 
with penicillins and is relatively non-toxic. Experiments performed to elaborate 
immunogenic and anaphylactic properties of SPC showed no allergy in guinea pigs. The 
anaphylactic activity was found to be of very low order with no mast cell degranulating 
action (46).  
 
Compared to the related aminoglycoside antibiotics, SPC appears to be neither 
ototoxic nor nephrotoxic (41). When administered at dosages up to 120 mg/Kg per day 
for 75-90 days, it showed no signs of cochlear or vestibular dysfunction in cats. When 
cattle were overdosed at 150 mg/Kg/day (10 times the labeled dose) for 5 days, there was 
increased relative kidney weight. Urinary pH decreased and squamous and transitional 
cells were found in the kidney (33). Clinical signs of ataxia and coma following a single 
90 mg s.c. injection were transient in turkey poults which resolved after 4 hours (38).  
 
Clinical experience indicates good tolerance of single i.m. dose of SPC. Tolerance 
studies in 25 healthy male volunteers who were given i.v infusions of SPC in doses 
ranging from 0.5 to 8 g/day for 5 consecutive days showed no signs of otoxicity 
(audiometric examinations), hepatotoxicity (SGPT, total bilirubin and alkaline 
phosphatase), nephrotoxicity (BUN, chemical and microscopic urinalysis) or local 
intolerance (evaluation of infusion sites) during the treatment (47). In another study, 
volunteers who were on daily 8 g dose for a longer duration of 21 days did not develop 
cochlear, vestibular, or renal abnormalities (48). In the much smaller doses used to treat 
gonococcal infections, adverse reactions such as dizziness, urticaria, nausea, chills, fever, 
and insomnia have been uncommon and serious adverse reactions have not been reported 
(41, 49).  
 
Comparison of the structural formula to aminoglycoside antibiotics suggests that 
SPC is a fused tricyclic molecule containing a unique aminocyclitol actinamin but not 
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aminosugar and because of this unique difference, it is speculated that aminosugar 
portions and their position in the antibiotic determine the degree of toxicity (48).  
 
 
Streptomycin 
 
Streptomycin (STM) is an antibiotic produced from the actinobacterium 
Streptomyces griseus. It was the first drug in the class of aminoglycosides and the first 
antibiotic that was effective in treating TB. It was originally discovered in 1944 by 
Schatz, Bugie and Waksman when they demonstrated its inhibitory action in vitro against 
tubercle bacilli (50, 51). 
 
 
Mechanism of Action and Indications 
 
STM is a bactericidal antibiotic that acts by interfering with normal protein 
synthesis. Its site of action is at the ribosomal protein S12 (rpsL) of the 30S subunit of the 
ribosome, and 16S rRNA (rrs) in the protein synthesis (52).  
 
Streptomycin is suggested in the therapy of tuberculosis, brucellosis, tularemia 
and yersinia infections, several of these require the co-administration of another agent 
(53). It is one of the first drugs that was active against Mycobacterium tuberculosis and is 
currently used as a second line agent against MTB when one or more of the first line 
agents are contraindicated because of toxicity,  intolerance or resistance. STM is also 
shown to be efficacious in the treatment of non-tuberculosis infections such as plague, 
tularemia, influenza (respiratory, endocardial, and meningeal infections), pneumonia, 
urinary tract infections, and gram negative bacteremia.  
 
 
Preclinical and Veterinary Pharmacokinetics 
 
Absorption 
 
STM is rapidly absorbed via the intramuscular route. Following i.m. 
administration of dihydro streptomycin (DSTM), a hydrogenated form of streptomycin, at 
a dose of 10 mg/Kg once daily for three days in cattle and sheep, mean Tmax was found to 
be about at 1.4 hr and 1.7 hr respectively, with average peak serum concentrations of 
approximately 23 mg/L (54). In dogs and swine, Tmax was found to be 60 min with an 
absorption half-life in swine of 14 min (55, 56). In a study performed in camels, 
following 10 mg/Kg i.m. administration of STM, the absorption half-life was found to be 
10.8 min with a mean peak serum concentration of 34.4 mg/L achieved 30 min after drug 
administration. Absolute bioavailability in camels via this route was found to be 98% 
(57).  
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Distribution 
 
STM administered via the i.v. and i.m. routes shows a bi-exponential disposition 
with the apparent volume of distribution numerically similar to the extracellular fluid 
volume. In a study performed to evaluate the pharmacokinetics of STM after i.v. and i.m. 
administration in horses, Vd was found to be 230 mL/Kg (58). In a similar study 
conducted in camels, mean Vd estimated by the area method was found to be 265 mL/Kg 
(57), where the extra cellular fluid volume in camels has been estimated to be 200 mL/Kg 
(59). In cattle, sheep and pigs Vd was found to be 0.39, 0.31 and 0.4 L/Kg respectively. 
 
Metabolism and Excretion 
 
STM does not undergo significant metabolism. Approximately two thirds of the 
administered dose is recovered in urine after 24 hours. The distribution half-life (t1/2α) in 
cattle was 0.71 hr and the elimination half-life (t1/2β) was 4 hr after a single 10 mg/Kg 
i.m. injection of STM (60). The t1/2β of STM in horses and camels was 3.4 hr and 4.7 hr 
respectively (57, 58) compared to 2-3 hr in humans (61). Urine pH in herbivores is 
alkaline whereas in humans it is more acidic and STM being a basic drug tends to be 
more unionized in alkaline pH leading to greater reabsorption from kidney tubules 
accounting for longer plasma half-lives in cattle, horses and camels (60). The mean 
systemic clearance of STM in horses, camels and cattle was found to be 0.79, 0.93 and 
1.58 mL/min/Kg respectively (57, 58, 60). In one of the studies of STM at 10 mg/Kg 
administered intramuscularly in lactating buffaloes, unchanged drug appeared in milk at 3 
hours and remained up to 8 hours with concentrations varying from 0.07 to 0.45 mg/L 
(60). 
 
 
Human Pharmacokinetics 
 
Absorption 
 
STM because of its poly-cationic nature is not absorbed following oral 
administration and hence parenteral injection is the usual method of administration, the 
i.m. route being the most common. A 1000 mg single daily dose (QD) or 500 mg twice 
daily dose (BID) results in peak serum levels of about 50-60 mg/L and 15-30 mg/L 
respectively within one hour of intramuscular administration (62). Oral administration of 
1 g daily dose does not produce significant concentrations in the blood and about 72 to 
110% of the daily dose could be detected in the feces. When STM is administered 
intrathecally there is a good retention of the drug in cerebrospinal fluid (CSF). A dose of 
15-20 mg results in concentrations from 13 to 25 mg/L of CSF after 24 hours (63). 
Continuous i.v. infusion of 3 g/day produces concentrations in the blood varying between 
20 to 60 mg/L (64).      
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Distribution 
 
STM is distributed into body tissues such as kidney, bile, lungs, heart and muscle, 
and fluids such as peritoneal, ascetic, synovial, intraocular and pleural fluid except for 
CSF. It passes through the placental barrier into the fetal blood and is also secreted into 
milk, saliva and sweat (64). About 30% of the drug is protein bound (65, 66). The volume 
of distribution is approximately 0.25 L/Kg (62). 
 
Metabolism and Excretion 
 
Approximately 50-60% of parenterally administered STM dose is excreted 
unchanged in the urine within first the 24 hours and total urinary excretion accounts for 
70-90% of the total dose in patients with normal renal function which is apparently 
accomplished by glomerular filtration (67). No metabolites have been identified for STM. 
About 2-5% of the drug is excreted in the bile and approximately 2% of the dose 
administered parenterally can be recovered from the feces which represents biliary rather 
than bowel excretion (64). The half-life of STM in humans is about 2-3 hours with 
clearance of 70 ml/min/m2 (65). Since STM has a low plasma protein binding and is 
excreted entirely by glomerular filtration, changes in renal function can significantly 
impact the clearance of the drug and hence dosage adjustments are needed in renally 
impaired patients.  
 
 
Toxicity 
 
STM adversely affects auditory, vestibular, and renal function in both animals and 
humans. Its toxic effects can be separated into acute and chronic effects. Acute effects are 
usually reversible and include neuromuscular blockade and acute hearing impairment. 
Chronic effects pose a major clinical problem and usually cause permanent damage to the 
individual. They include damage to the kidney and the inner ear (68, 69).  
 
Nephrotoxicity 
 
The proximal renal tubule is the major site of damage exerted by STM. Although 
the exact chain of events in STM nephrotoxicity is unclear, accumulation of drug and 
phospholipids within lysosomes is involved. The lysosomes become overloaded with 
phospholipid, destabilize and rupture leading to release of acid hydrolases and of high 
concentrations of aminoglycoside into the cytoplasm where they disrupt cell structure and 
function (70). In a study, where a total dosage of 75 mg/Kg/week of  STM was given 
either as a 30 min i.v. infusion administered daily (15 mg/Kg given Monday to Friday) or 
3 times weekly (25 mg/Kg administered Monday, Wednesday, and Friday), 19% of the 
patients developed nephrotoxicity, which was defined as an increase in the serum 
creatinine level of  > 0.5 mg/dL for patients with baseline serum creatinine levels 
between 0.5–1.9 mg/dL (71). Prolonged duration of therapy, greater total dose, 
hypotension, volume depletion, high peak or trough serum concentrations, concurrent 
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liver disease, and concurrent use of other nephrotoxic drugs are shown to be risk factors 
pertaining to STM ototoxicity (72-74).  
 
Ototoxicity 
 
Ototoxicity is characterized by an early symptom tinnitus. Discontinuance of the 
drug at this stage can probably prevent auditory loss. Hearing loss occurs as a result of 
degeneration of the hair cells of the cochlear, beginning at the basal coil and progressing 
to the apex. Loss starts with high frequencies followed by loss of lower frequencies (75). 
Within the vestibular apparatus, hair cell damage starts in the apex of the cristae and the 
striolar regions of the maculae and progresses towards the periphery of the vestibular 
receptor (76). Along with the sensory cells, afferent nerve endings deteriorate. STM 
predominantly causes vestibulotoxicity whose symptoms include disequilibrium and 
ataxia (77). Proposed risk factors include genetic predisposition and total dose 
administered (78, 79). The onset occurs approximately at the end of the fourth week of 
therapy with daily doses ranging from 1 to 2 g and about the third week with higher doses 
of 3 g daily (80).  
 
 
Classification of In Vitro PK/PD Models 
 
In vitro PK/PD models have many favorable characteristics such as flexibility, 
adaptability, relatively low cost, good correlation with human and animal data, and no 
ethical concerns as compared to animal experiments which make them excellent 
experimental platforms (81). Especially with antituberculosis drugs, the drug-
mycobacterial interaction can be measured more precisely than in vivo since the influence 
of the immune system is absent in such models. On the basis of drug exposure and 
bacterial concentration these in vitro models can be classified into static models and 
dynamic models. 
 
 
Static Models 
 
As the name suggests, static models evaluate how a bacterial culture responds to a 
constant environment with a fixed antibiotic exposure. Since there is no exchange of 
medium in these systems and bacteria utilize the same medium during the course of the 
experiment, their growth is limited by nutrition, space, aeration and toxic metabolites in 
addition to the effect of the antibiotic (13). However, MIC determined from such a setup 
is the most prevalent and best understood in vitro PD parameter for antibiotics, which is 
used routinely to track antibacterial resistance in clinical isolates (82). Although these 
models have been extensively used (83-87), they cannot provide information on the time 
course of antimicrobial activity under varying antibiotic concentrations as observed in 
vivo and since MIC determination depends on the number of bacteria at a given time 
point, many different combinations of growth and kill rates can result in the same MIC 
(13). However, these models when studied with a range of constant antibiotic 
concentrations over a period of time can provide useful information on the kill kinetics, 
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which approximates a constant infusion scenario of an intravenous antibacterial agent in 
vivo.  
 
The application of such models for studying the PK/PD relationships of the 
antituberculosis agents rifampin (RIF), isoniazid (INH) and fluoroquinolones such as 
moxifloxacin (MXF), ofloxacin (OFX), sparfloxacin (SPX), and ciprofloxacin (CIP) has 
been reported by Jayaram et al. (88-90), and is presented in panel A of Figure 1-2. The 
kill kinetics were determined in BACTEC 7H12B medium, followed by plating on 7H11 
agar plates to obtain colony counts. The MTB culture was inoculated into BACTEC vials 
which were monitored daily by a radiometric detection method using the BACTEC TB 
460 system, in which the mycobacterial growth is determined by the utilization of 14C 
with release of 14CO2 by the multiplying bacteria. Fixed drug concentrations ranging 
from high to low were added to the vials and samples from the cultures with each 
concentration along with a drug free control were plated over 9 days to determine the 
CFU/mL. Time-kill curves were plotted and analyzed for the rate and extent of bacterial 
killing. Rate of killing was determined from the start of experiment to the time of 
maximal reduction in the log10 CFU/mL and in vitro dose response curves were obtained 
by plotting the log10 CFU/mL against the ratio of the concentration to its MIC in broth 
(Cbroth/MIC). Each fixed concentration of the drug was multiplied by the time of exposure 
to get AUC which was then divided by MIC in broth to obtain the AUC/MIC index. The 
results from these studies allowed the authors to quantify PD parameters that could 
describe the in vitro bactericidal efficacy and indicated AUC-dependent killing for RIF, 
concentration-dependent killing for INH, and a time-dependent killing for 
fluoroquinolones.    
 
 
Dynamic Models 
 
Any typical dosage regimen for antituberculosis drugs involves periodic 
administration of the antibiotic with varying drug concentrations at the effect site due to 
in vivo absorption, distribution and particularly clearance mechanisms.  As bacteria react 
to these changing concentrations differently than to exposure to constant concentrations, 
it is important to mimic similar conditions in vitro to understand the rate and extent of 
bacterial kill by the respective antibiotic under these conditions. Dynamic models utilize 
time-kill curves, which follow the microbial killing and growth as a function of both time 
as well as antibiotic concentration. These dynamic models used to study the PK/PD of 
antituberculosis agents can be further differentiated as follows: 
 
Type I: Models without Filters Involving Bacterial Loss, Where the Mechanism of Drug 
Loss Involves Dilution 
 
In order to simulate in vivo drug clearance, a systematic loss of drug from the 
model becomes essential. This was usually achieved in early models via dilution 
performed in a stepwise or continuous manner. To a culture vessel containing actively 
growing bacteria, a known volume of culture was either substituted with fresh medium 
lacking the antibiotic at fixed intervals or it was infused using a peristaltic pump where  
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Figure 1-2. In vitro PK/PD models for antituberculosis agents. Panel A shows a static 
model where C1 to C5 denote a series of concentrations of a drug and T1 to T4 denote 
times at which aliquots of mycobacteria are plated for every given concentration of drug. 
Panel B shows a dynamic model with filter assembly involving no bacterial loss and the 
mechanism of drug loss involves simple dilution by the media. Panel C shows a hollow 
fiber model where there is no bacterial loss and the mechanism of drug loss involves 
diffusion into extra capillary compartment. 
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the excess was directed into waste. Although these models mimicked a one compartment 
pharmacokinetic model, they suffered from dilutional loss of bacteria (91, 92). Loss of 
bacteria from the model leads to a bias which can be corrected using mathematical 
equations (93, 94). However, for slow growing organisms, the resulting bias may be 
substantial and inadequate for mathematical correction. Therefore no such models have 
been reported so far for studying antituberculosis agents.  
 
Type II: Models with Filters Involving No Bacterial Loss, Where the Mechanism of Drug 
Loss Involves Dilution 
 
The use of filters or membranes which do not allow the bacteria to be washed out 
are alternative approaches to overcome the issue of bacterial loss. A modified version of 
type I models involving a filter to prevent bacterial loss and a stirrer to prevent blockage 
of the filter membrane and to maintain the homogeneity of the culture has become 
popular to study the effects of antibiotics. One such model to evaluate time-kill curves of 
antituberculosis drugs against mycobacteria has recently been reported by Budha et al. 
(19).  
 
The in vitro system, as shown in panel B of Figure 1-2, consisted of a two-armed, 
water jacketed spinner culture flask, where a filter unit, consisting of a pre-filter (5 µm) 
and filter membrane (0.22 µm), was used to prevent leakage of bacteria during the 
dilution process. One of the arms covered with silicone septa was used for dosing and 
repeated sampling. The other arm was connected to a reservoir containing antibiotic free 
sterile medium. The whole filter unit was suspended into the media from the top via a 
hollow steel tube whose outlet was connected to a peristaltic pump to continuously 
withdraw the medium at a constant rate. The flask was placed on a magnetic stirrer, 
which ensured homogeneity of the culture and also prevented membrane pore blockage. 
The temperature in the flask was maintained at 37 ⁰C for bacterial growth by attaching a 
thermostatic water circulator to the water jacket of the flask. In this model, mycobacteria 
were exposed to INH concentration-time profiles as encountered during multiple dose 
regimens with 25, 100 and 300 mg/day in humans who are either fast or slow INH 
metabolizers or the resulting time-kill curves were obtained. The different elimination 
half-lives (t1/2) of INH in slow vs. fast metabolizers were simulated in the model by 
varying the flow rates of the medium. The results from this study confirm that AUC0-24/ 
MIC is the most explanatory PK/PD index for the antimicrobial effect of INH.  
 
Type III: Hollow Fiber Models Involving No Bacterial Loss, Where the Mechanism of 
Drug Loss Involves Diffusion 
 
In spite of the modifications in type II models, membrane pore blockage could be 
a problem which may become more pronounced when antibiotics with short half-lives are 
studied, since the flow rate across the filter is higher (95). In order to overcome this 
problem, a diffusion or dialysis of the drug to create the desired antibiotic concentration 
profile in a separate bacterial compartment has been employed by several groups (96-98).  
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Gumbo et al. (99-104) published several studies of the antituberculosis agents 
RIF, INH, MXF and pyrazinamide (PZA) utilizing a hollow fiber bioreactor system, 
which is an example of a diffusion model. Hollow fiber systems represent a two 
compartment model. The central compartment of the hollow fiber system is composed of 
the central reservoir, the inner lumina of the hollow fiber capillaries, and the oxygen-
permeable flow path connecting the central reservoir to and from the hollow fibers. The 
peripheral compartment is the space outside the hollow-fiber capillaries that is enclosed 
by an impermeable plastic encasement. The hollow fiber bioreactor system allows MTB 
to grow in the peripheral compartment of a hollow fiber cartridge. This peripheral 
compartment is separated from the central compartment by semi-permeable hollow 
fibers, with pore sizes that selectively allow transfer of nutrients, drugs and bacterial 
metabolites but restrict bacteria from leaving the peripheral compartment, as shown in 
panel C of Figure 1-2. In these experimental systems, computer controlled peristaltic 
pumps are used to administer drugs via a dosing port and fresh 7H9 broth is pumped into 
the afferent port of the central compartment of the hollow fiber system, while drug-
containing media is iso-volumetrically removed from the efferent port of the system at 
rates programmed to simulate the drug half-life encountered in humans.  
 
These in vitro models were used to study a wide variety of issues such as 
selection of MXF doses that suppress drug resistance (99), to understand reasons for 
failure of CIP (100) and INH treatment (101), to predict efficacy of INH in different 
ethnic populations (102), and to evaluate the PK/PD parameters of RIF (103) and PZA 
(104). Dose-effect and dose-scheduling studies were also performed with ethambutol to 
identify exposures and schedules linked to optimal kill and resistance suppression (105). 
In spite of these advancements, there are limitations associated with the use of the hollow 
fiber bioreactor models. These bioreactors are complex and difficult to sterilize between 
experiments, and hence new hollow fiber cartridges are recommended for every study.  
 
 
Perspectives Relevant to Drug Development 
 
The use of in vitro models in drug development has increased tremendously in the 
recent past.  Several scenarios for evaluating the activity of new molecules can be studied 
using these models MIC does not provide any information on the persistence of antibiotic 
effects. Such inhibitory effects that persist after exposure to an antibiotic can be studied 
in these models. Also, antituberculosis therapy is a combination of several antibiotic 
agents which is further complicated when treating patients co-infected with HIV, and it is 
challenging to study the different drug combinations in vivo from a drug development 
perspective.   
 
Whole blood bactericidal assays, serial sputum colony counting and liquid culture 
have been used in Phase II studies to look at different combinations of drugs albeit not 
exhaustively and only with specific regimens of particular interest.  In vitro models are 
reasonably simple to quantitatively assess the efficacy of such combinations and to 
perform more comprehensive experiments addressing these questions. Since it is 
relatively easy to study antimicrobial activity of drugs against different strains of bacteria 
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in these systems, these models may also serve as useful tools to study the emergence of 
resistance and help identify novel drugs or combinations thereof to treat drug resistant 
strains. 
 
Owing to the fact that these in vitro PK/PD techniques are relatively new in the 
area of antituberculosis drug development and tedious to work with because of the long 
doubling times of mycobacteria, only limited or no studies have been reported pertaining 
to the following three sections. Hence we provide an insight into how these scenarios can 
be explored in the future using such in vitro models.  
 
 
Postantibiotic Effect  
 
The rate of bacterial killing and time before re-growth of surviving bacteria 
influences the design of an optimal dosing interval. Postantibiotic effect (PAE) refers to 
the continued suppression of bacterial growth following limited exposure of organism to 
an antibacterial agent (106). It can be demonstrated in vitro by observing bacterial growth 
after a drug is removed. The standard method to quantitate PAE is to calculate the 
difference in time required for drug-exposed and control cultures to increase one log10 
above the number present immediately after withdrawal of the antibiotic (107). The PAE 
using bacterial counts as a parameter is calculated by PAE = T – C, where T is the time 
required for bacterial counts of drug-exposed cultures to increase one log10 above the 
counts observed immediately after washing/dilution and C is the corresponding time 
required for counts of untreated cultures (108).   
 
PAE has been used to determine the optimal interval between dosing and is the 
basis of twice or thrice weekly therapy for TB. Administration of drugs at less frequent 
dosing intervals may not only improve patient compliance but may also reduce toxicity 
and costs involved in the treatment. Studies performed using static models with INH, 
RIF, Streptomycin (SM), Ethambutol (EMB), Rifapentine and MXF have each 
demonstrated postantibiotic effects against MTB (109, 110). Prolonged PAEs are usually 
observed with antibiotics that are inhibitors of protein synthesis or nucleic acid synthesis. 
In other words, concentration-dependent antibiotics tend to have larger PAEs (14). For 
drugs with concentration-dependent bactericidal action the rate of bactericidal activity is 
maximal at the Cmax and higher doses of the drug not only increase the rate of reduction 
of bacteria, but also the length of time of drug exposure to bactericidal concentrations. 
Therefore the higher the drug concentration, the longer is the duration of the PAE for 
these drugs, and the less is the residual bacterial population at the time of the next dose 
(110). Hence from a PK/PD standpoint, large doses can be administered at longer dosing 
intervals because prolonged PAE protects against the bacterial re-growth when 
concentrations fall below the MIC.  
 
Bacteria exposed to sub-MIC concentrations of antibiotics may undergo adaptive 
changes with modifications in cell wall structure, changes in ribosome density, or 
formation of filaments. In addition to morphological changes, sub-MICs may also have a 
direct inhibitory effect on the bacterial growth in vitro (111). Postantibiotic sub-MIC 
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effect (PA SME) is another useful parameter which measures such effects of sub-MIC 
drug concentrations on bacterial growth following serial exposure to drug concentrations 
exceeding the MIC. This can be calculated as PA SME =Tpa – C, where Tpa is the time 
taken for the cultures previously exposed to antibiotics and then exposed to a sub-MIC to 
increase by one log10 above the counts observed immediately after washing/dilution and 
C is the corresponding time for the unexposed cultures (108). 
 
Ginsburg et al. reported PAE properties of fluoroquinolones against MTB using 
an in vitro PK/PD model (112). By simulating PK parameters in humans, they 
determined the PAE of a single 400-mg dose of MXF on MTB to be over 1 week 
compared to a PAE of greater than 15 days in a traditional static in vitro study of MXF 
after an exposure period of 24 h. Thus, such models can be effectively used to evaluate 
the post antibiotic effect of existing antimycobacterial agents by simulating a particular 
dosing regimen in vitro and studying the growth and kill rates after cessation of that 
specific therapy.  
 
 
Evaluation of Combination Therapy 
 
Simultaneous administration of antibiotics is always practiced in antituberculosis 
therapy because of the high potential for the development of TB drug resistance using 
monotherapy and the differing drug sensitivities of active and latent populations of the 
TB bacilli found within an established infection. There has also been substantial interest 
in novel combinations of new compounds with existing drugs to block the emergence of 
drug resistance and to shorten the duration of therapy. Testing new drugs or drug 
combinations for activity against tuberculosis in vivo is a highly expensive and time-
consuming process in animal models, and is largely prohibitive in humans for ethical 
reasons. In vitro models provide an inexpensive and rapid alternative for optimizing drug 
combinations before they proceed to preclinical or clinical testing. They also allow a high 
degree of standardization to study drug-receptor interactions without other interfering 
biological processes.  
 
There are several existing methods to study antibiotic combinations in vitro. 
These include checkerboard techniques with tube dilutions or microtiter apparatus, the 
agar dilution method and various forms of disc proximity tests and paper strip methods 
(12, 113-115). However, all these methods involve constant concentrations of antibiotics 
to evaluate their activity.   
 
When studying the combination of drugs and their time-kill curves in in vitro 
PK/PD models, differences in their pharmacokinetic properties can be taken into account. 
One of the major setbacks in this approach, however, is the complexity involved in 
effectively simulating concentration-time profiles of drugs with different half-lives. In 
spite of these intricacies, in vitro PK/PD models for simultaneous simulation of serum 
kinetics of two or more drugs with different half-lives have been developed against fast 
growing organisms such as Streptococcus pneumonia and Staphylococcus aureus (96, 
116-119). Although no examples have yet been reported for mycobacteria, similar 
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models could likely be used to evaluate the synergistic potential of novel combinations of 
antituberculosis agents.    
 
 
Resistance 
 
Emerging resistance threatens the usefulness of available treatment options 
against the multi drug resistant mycobacteria.  For example, MDR-TB takes about 18-24 
months of therapy for complete cure as compared to a six month therapy against a 
susceptible strain. This prolonged duration of therapy is oftentimes also associated with 
severe toxicity related to the applied second line agents leading to poor patient 
compliance. Thus, it is desirable to develop novel drugs or drug combinations that are 
safe and effective against MDR strains. In vitro PK/PD models can be effectively used to 
study such resistant clinical isolates for developing new molecules or new regimens with 
existing drugs. Conditions that can lead to resistant strains can be simulated and such 
resistant strains can further be studied.  
 
Tam et al. used a hollow fiber model to examine the relationship between 
garenoxacin (a des-fluoroquinolone) and the likelihood to select resistant strains with 
different and escalating free area under the concentration-time curve over 24 h 
(AUC24)/MIC exposures of the drug for 48 h (120).The authors suggested that low 
AUC24/MIC ratios between 10 to 35 were optimal for maximally amplifying the pre-
existing resistant subpopulation. Exposures in excess of these ratios amplified the 
resistant subpopulation sub optimally, until an exposure was achieved that kept the 
number of resistant clones at or below the number present at the initiation of the 
therapeutic pressure resulting in an “inverted-U” shape for the function linking drug 
exposure to suppression of the resistant subpopulation.  
 
Mutant prevention concentration (MPC) defines the antimicrobial drug 
concentration threshold that would require an organism to simultaneously possess two 
resistance mutations for growth in the presence of the drug. For M. bovis BCG, the MPC 
is estimated by determining the minimal antibiotic concentration that results in recovery 
of no mutants when large numbers of cells are applied to antibiotic-containing agar 
plates. The use of large numbers of cells, on the order of 1010 ensures that the restrictive 
antibiotic concentration blocks the growth of first-step mutants (121).  
 
In one of the studies, the association between MPC based PK/PD parameters 
(AUC/MPC, Cmax/MPC or T >MPC) and emergence of resistant mutants of 
Streptococcus pneumoniae was evaluated for fluoroquinolones using an in vitro PK/PD 
model. The results from this study identified AUC0-24/MPC and Cmax/MPC indices to be 
associated with emergence of resistance (122). Although no such studies have been 
performed using mutants of MTB for emergence of resistance against antimycobacterials, 
it is plausible to evaluate these scenarios using in vitro PK/PD models. 
 
Population analysis profiles (PAP) is a specialized technique initially developed 
to detect vancomycin resistance but it can be applied to study drug resistant MTB strains.  
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This technique compares the AUC of viable counts versus concentration profile of a 
strain under study against a control resistant strain after a given period of incubation. 
Based on this ratio one can determine if the test strain is a resistant one or not.   
 
For example, in case of vancomycin resistant Staphylococcus aureus (VRSA), a 
ratio of AUC of a test strain against AUC of a hetero-resistant control strain Mu3 is 
calculated.  This ratio exceeding 0.9 is used as a criterion to establish a vancomycin 
hetero-resistant S. aureus (hVRSA) (123, 124). In vitro PK/PD models can be used to 
perform such analyses. They can also be used to study the population dynamics of the 
susceptible and resistant strains over time following a particular dosage regimen (81). 
Although no such reports have been published so far for antituberculosis drugs, similar 
studies can be performed using MDR TB and XDR TB in order to establish effective 
dosing regimens against drug resistant strains. 
 
 
Pharmacokinetic/Pharmacodynamic Data Analysis 
 
PK/PD modeling and simulation techniques are increasingly used in drug 
development in a variety of indications. Such techniques allow characterizing the time 
course of the effect intensity resulting from a certain dosing regimen (2) and have been 
widely applied to antibiotics for evaluating their pharmacodynamics (their initial rate of 
the bacterial killing and the re-growth of bacteria) and to obtain a relevant PK/PD index 
which correlates with a therapeutic outcome.  
 
Mathematical modeling of drug effects maximizes the information gained from an 
experiment, provides further insight into the mechanisms of drug effects and allows for 
simulations in order to design studies or even derive clinical treatment strategies (125). 
Modeling approaches can be classified into mechanism-based or empirical.  
 
 
Mechanism Based Modeling for Estimating PK/PD Parameters 
 
A mechanistic model is by definition a mathematical model based on known or 
hypothesized mechanisms of behavior of a biological system. The parameters are in 
accordance with pharmacokinetic, physicochemical, biophysical, physiological and 
patho-physiological principles, and have direct identifiable biological or biophysical 
interpretation (126). Mechanism based models for antimicrobials utilize drug 
concentrations and relate them to their effect. They are commonly applied to estimate the 
PK/PD parameters of antibiotic drugs and have to include at least a submodel of 
microorganism replication, a submodel of antimicrobial drug effects and a submodel for 
changing drug concentrations (pharmacokinetic submodel) (125). Since these models are 
limited to in vitro data, a host defense submodel is usually not included. 
  
The submodel for microorganism replication is most commonly modeled using 
the following equation: 
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 ௗேௗ௧ ൌ ܰ · ݇௥௘௣௟௜௖௔௧௜௢௡ െ ܰ · ݇ௗ௘௔௧௛ Eq. 1-1 
 
where N is the number of microorganisms and the first-order rate constants kreplication and 
kdeath describe natural replication and death of microorganisms in the absence of 
antibacterial agents. This model, however, is based on the underlying assumption that the 
number of microorganisms N that can replicate is the same as the number subjected to 
death. Also this model cannot adequately describe the decrease in the net growth rate as 
the system approaches the stationary phase of bacterial growth. kgrowth or kapparent, a first 
order rate constant for observed growth, which is the difference between kreplication and 
kdeath is often applied because of difficulties in separating microorganism replication and 
death by a traditional kill curve analysis (125). 
 
Increased knowledge regarding the production and the nature of persister cells, 
i.e., cells with reduced growth rates and reduced antibiotic susceptibilities can be 
efficiently applied to build mechanism-based PK/PD models (127). Nielsen et al. 
described a semi-mechanistic PK/PD model for assessment of antibacterial agents where 
the total bacterial population was divided into growing (S) and resting (R) population 
allowing a transfer from the growing population to the resting population as the total 
population approaches the stationary phase.  Mathematically this can be modeled using 
the equations below: 
 
 ௗௌௗ௧ ൌ  ܵ · ݇௚௥௢௪௧௛ െ ܵ · ݇ௗ௘௔௧௛  െ  ܵ · ݇ௌோ Eq. 1-2 
 
 ௗோௗ௧ ൌ   ܵ · ݇ௌோ െ ܴ · ݇ௗ௘௔௧௛ Eq. 1-3 
 
where kSR is the transfer rate constant (128).  
  
To incorporate the antimicrobial effect, a submodel of antimicrobial drug effect 
relating the drug concentrations to the microbial survival is often described using the 
following equation:  
 
 ௗேௗ௧ ൌ ܧ௥௘௣௟௜௖௔௧௜௢௡ · ܰ · ݇௥௘௣௟௜௖௔௧௜௢௡ െ ܧௗ௘௔௧௛ · ܰ · ݇ௗ௘௔௧௛ Eq. 1-4 
 
The Emax model can be used to describe between drug concentration and its effect 
on replication and death rate of the bacteria. The maximum effect obtained when 
determining a concentration-effect relationship (Emax) and the concentration required to 
produce half-maximal effect (EC50) are PD parameters used in defining the Emax model. 
The Emax model can also be used to describe the relationship between a PK/PD index and 
the effect. Drug effect decreasing the replication rate (Ereplication) can be modeled using an 
inhibitory sigmoid Emax model shown below: 
 
 ܧ௥௘௣௟௜௖௔௧௜௢௡ ൌ 1 െ  ூ೘ೌೣ · ஼
ം
ூ஼ఱబം ା஼ം
 Eq. 1-5  
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where Imax is the maximum inhibitory effect, C is the drug concentration, γ is the Hill 
coefficient and IC50 is the concentration that produces half-maximal inhibition. 
 
Drug effect leading to increased death rate (Edeath) can be modeled using a 
stimulatory sigmoid Emax model as follows: 
 
  ܧௗ௘௔௧௛ ൌ 1 ൅ ா೘ೌೣ · ஼
ം
ா஼ఱబം ା஼ം
 Eq. 1-6 
 
where Emax is the maximum stimulatory effect, C is the drug concentration, γ is the Hill 
coefficient and EC50 is the concentration that produces half-maximal stimulation leading 
to death. 
 
It is well known that bacteria show different growth phases and that antibiotic-
induced killing often shows an initial phase with rapid killing, followed by a decline in 
the killing rate with time. Therefore ignoring the replication inhibition and including 
stimulation of death rate in Eq. 1-4 leads to the equation shown below: 
 
 ௗேௗ௧ ൌ  ܰ · ݇௥௘௣௟௜௖௔௧௜௢௡ െ ܰ · ݇ௗ௘௔௧௛  ൬1 ൅ 
ா೘ೌೣ · ஼ം
ா஼ఱబം ା஼ം
 ൰ Eq. 1-7 
 
with observed growth ሺ݇௚௥௢௪௧௛ ൌ  ݇௥௘௣௟௜௖௔௧௜௢௡ െ ݇ௗ௘௔௧௛ሻ and a maximum kill 
rate ሺ݇௞௜௟௟ ݋ݎ ݇௠௔௫ ൌ ݇ௗ௘௔௧௛ ·  ܧ௠௔௫ሻ, this equation can be further transformed into the 
most frequently applied PK/PD model for antibacterial drugs (125): 
 
 ௗேௗ௧ ൌ  ܰ · ݇௚௥௢௪௧௛ െ ܰ · ݇௠௔௫ ·
 ஼ം
ா஼ఱబം ା஼ം
 Eq. 1-8 
 
The pharmacokinetic submodel describes the relationship between dose or dosing 
regimen and drug concentrations with time. Depending on the in vitro setup, this can be 
modeled as a one compartment model or a multi-compartment model. Assuming dosing 
by an intravenous bolus administration, a general form of the model can be defined as: 
 
 ܥ௧ ൌ ܣଵ݁ିఈభ௧ ൅ ܣଶ݁ିఈమ௧ ൅ … .൅ܣ௡݁ିఈ೙௧ Eq. 1-9 
 
where A1 to An are coefficients, α1 to αn are first order rate constants and n denotes the 
number of compartments.  This submodel can also be applied to approximate the 
concentration-time profiles for orally administered drugs that are rapidly absorbed. 
 
Budha et al. reported the relationship between INH exposure and mycobacterial 
kill using a modified version of Eq. 1-8 as shown below, which was initially developed 
for Voriconazole against Candida isolates (19, 129):    
 
 ௗேௗ௧ ൌ ቂ݇଴ · ቀ1 െ
ே
ே೘ೌೣቁ െ ሺ1 െ ݁
ିఈ·௧ሻ · ቀ ூ೘ೌೣ·஼ூ஼ఱబା ஼ቁቃ · ܰ Eq. 1-10 
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where N is the mycobacterial cell counts in CFU/mL, k0 is the bacterial net growth rate 
constant, Nmax is the maximum number of bacteria in the system in CFU/mL, Imax is the 
maximum kill rate, C is the concentration of INH at time t, and IC50 is the concentration 
at half-maximal kill rate. A logistic growth function, 1-N/Nmax was used to describe the 
limited growth of bacteria in the absence of INH.  
 
The authors reported a delay in bacterial kill which can likely be due to the time 
necessary to achieve sufficient intracellular drug exposure to initiate the killing process 
that was modeled using the term 1 െ ݁ିఈ·௧, where ߙ is the delay rate constant.  
 
When studying pharmacodynamics of antibiotics against MTB, an adaptive IC50 
is often used (19, 102, 129). This model component is necessary to explain the change in 
IC50 over the course of treatment due to an increase in drug insensitive cell population, 
for example due to latency for Mycobacterium species. The adaptive IC50 can be modeled 
using the equation below:       
 
 ܫܥହ଴,஺ ൌ ܫܥହ଴ · ݁൬
ೖೌ೏ೌ೛೟ೌ೟೔೚೙.ಿబ
ಿ·ಲೆ಴బషమర ൰·௧ Eq. 1-11 
 
where IC50,A is the adaptive IC50, N0 is the number of bacterial cells at time zero, N is the 
cell count in CFU/mL, kadaptation is the adaptation constant and IC50 is the baseline IC50. 
 
Gumbo et al. reported a mechanistic PK/PD model for MXF (99) which has been 
further applied in modeling INH (101) and RIF (103) PK/PD data. The resultant changes 
in the drug-resistant [R] and the drug-sensitive [S] Mycobacterium tuberculosis 
population were described using the equations below: 
 
 ௗேೄௗ௧ ൌ ݇௚௠௔௫ିௌ   · ሺ1 െ ܮௌሻ   ·   ௌܰ   · ܧ െ ݇௞௠௔௫ିௌ   · ܯௌ   ·   ௌܰ Eq. 1-12 
 
 ௗேೃௗ௧ ൌ ݇௚௠௔௫ିோ   · ሺ1 െ ܮோሻ   ·   ோܰ   · ܧ െ ݇௞௠௔௫ିோ   · ܯோ   ·   ோܰ Eq. 1-13 
 
where each subpopulation has an independent growth rate constant (drug sensitive, Kgmax-
S, drug resistant, Kgmax-R). Bacteria at the site of infection which were in the logarithmic 
growth phase in the absence of drug exhibited an exponential density-limited growth rate 
described by the following equation: 
 
 ܧ ൌ 1 െ ሺ ோܰ ൅ ௌܰሻ/ܱܲܲܯܣܺ Eq. 1-14 
 
where E is the logistic growth term, and the maximal bacterial density (POPMAX) is 
identified as part of the estimation process. The authors allowed drug to affect the growth 
rate independently of kill through a saturable Michaelis-Menten type kinetic event (L), 
and the killing effect of the drug was modeled as a saturable Michaelis-Menten type 
kinetic event (M) that relates the kill rate to drug concentration, where C50-g and C50-k is 
the drug concentration at which the bacterial growth or kill rate is half-maximal as 
described in the following equations: 
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 ܮ ൌ   ቀ௑భ௏಴ቁ
ு   ൤ቀ௑భ௏಴ቁ
ு  ൅ ܥହ଴ି௚ு൨൘  Eq. 1-15 
 
 ܯ ൌ ቀ௑మ௏಴ቁ
ு   ൤ቀ௑మ௏಴ቁ
ு  ൅ ܥହ଴ି௞ு൨൘  Eq. 1-16 
 
where H is the slope constant, X1 and X2 are the amounts of drug in the central and the 
peripheral compartments of the hollow fiber system, respectively, and Vc is the volume of 
the central compartment of the hollow fiber system. For drug-sensitive and drug-resistant 
populations as expressed in Eq. 1-13 and Eq. 1-14, there are separate terms for H, C50-g 
and C50-k. 
 
 
Empirical Modeling for Identifying Appropriate PK/PD Indices 
 
An empirical model is a non-mechanistic model whose parameters may be 
adequate for describing the longitudinal data at hand but does not take to underlying 
biological mechanisms into account. It can be predictive when used in conditions 
sufficiently similar to the ones already studied, but has usually limited predictability 
beyond these conditions (126). A typical empirical modeling exercise utilizes a time-
integrated measures of exposure, such as AUC or dose, from in vitro time-kill 
experiments to determine the primary PK/PD index responsible for the antibacterial 
effect and to understand whether a molecule exhibits a time-dependent or an exposure-
dependent killing pattern.  
 
AUC/MIC, Cmax/MIC and T >MIC, as discussed in the previous sections, are the 
three most commonly used PK/PD indices to evaluate antibacterial effects. Using a 
combination of dose escalation, fractionation and different strains one can identify the 
best suitable index related to the antibacterial effect for a specific compound (81). A 
sigmoid inhibitory dose-response model is one of the most frequently used models to 
characterize antimicrobial activity. For instance, in one of the recent studies for 
identification of the most appropriate empirical PK/PD index associated with the 
microbial kill of the first line antituberculosis agent INH, viable cell counts on different 
days following multiple dosing of INH were analyzed using an inhibitory Emax model 
shown below: 
 
 ܧ ൌ ܧ௖௢௡௧௥௢௟ െ ቀா೘ೌೣ·௉௄௉஽ா஼ఱబା௉௄௉஽ቁ Eq. 1-17 
 
where E is the observed M. bovis BCG cell counts in log10CFU/mL, Econtrol is the cell 
count in the control experiment, and Emax is the maximal antimicrobial effect in 
log10CFU/mL. EC50 is the value of the PK/PD index that produces half-maximal  
antimicrobial effect and PKPD is one of the empirical PK/PD indices AUC0–24/MIC, 
T>MIC or Cmax/MIC. INH exhibited exposure-dependent antibacterial activity on M. 
bovis BCG where the empirical PK/PD index AUC0-24/MIC was found to be well 
associated with the microbial kill (19).  
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For the first line antituberculosis agents INH, RIF and Pyrazinamide (PZA) and 
second line fluoroquinolones and aminoglycosides, a concentration dependent killing 
pattern that correlates best with AUC/MIC ratio is shown to be a reliable predictor of 
efficacy (19, 99-104).  
 
 
Drawbacks of In Vitro Models 
 
In spite of the potential advantages of in vitro models discussed in this 
manuscript, these models are obvious simplifications of in vivo scenarios and therefore 
come with certain drawbacks which cannot be ignored.  These can be classified under 
host factors, pathogen factors and pharmacokinetic factors.   
 
 
Host Factors 
 
The host immune system plays a major role in TB. Most infected 
immunocompetent individuals fail to progress to full-blown disease because the MTB 
bacilli are directly killed by macrophages or walled off by the immune system inside a 
tissue nodule known as a granuloma. The granuloma’s primary function is to contain and 
prevent the dissemination of the mycobacteria (130). Human tuberculous granulomas 
contain an organized collection of differentiated and activated macrophages, T-
lymphocytes, some B-lymphocytes, dendritic cells, neutrophils, fibroblasts and 
extracellular matrix components that limit nutrient delivery to the core (131). Bacteria are 
often found multiplying inside macrophages around the edge of the necrotic center of a 
granuloma. In vitro PK/PD models lack the ability to mimic this complex host defense 
mechanism and therefore approximate more to conditions of an immunodeficient patient 
where the infection is more bacteremic in nature (92). However, during the reactivation 
phase of the disease the majority of the bacilli in pulmonary cavities reside extracellularly 
(132), and hence the results obtained from in vitro models may be reflective of the in vivo 
killing under this condition. 
 
Besides the lack of immune response, physiological conditions also vary between 
in vivo and in vitro setups leading to differences in antituberculosis activity. For example 
the front line antituberculosis drug pyrazinamide is inactive in normal culture conditions 
and is only active at acidic pHs that are thought to mimic those experienced by bacteria in 
activated macrophages. The tuberculosis granuloma is also believed to be subjected to a 
gradient of microaerophilic/ anaerobic conditions which limits growth.  Since these 
conditions are technically difficult to simulate in vitro, antibacterial efficacy can differ 
significantly between the in vitro model and the in vivo environment.    
 
 
Pathogen Factors 
 
The growth rate for most bacteria is faster in vitro compared to growth in vivo or 
in human serum.  Since antimicrobial efficacy in an in vitro model relates to the rate of 
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bacterial growth, this can be a potential limitation of in vitro models, especially when 
there are significant differences in the growth rates (133, 134). Biochemical data suggest 
that MTB growing in vivo upon granuloma formation shifts to anaerobic metabolic 
pathways. It has also been shown that tubercle bacilli are able to shift into a non-
replicating drug tolerant state when nutrients are depleted. This process gives MTB the 
capability to lie dormant in the host for long periods of time and this results in differences 
in growth conditions in vitro and in vivo (23).  
 
Furthermore, the growth rate of MTB within the infected host varies according to 
the type of lesion such as extracellular and actively multiplying bacilli in the liquefied 
caseous material covering the cavity wall, semi-dormant bacilli with intermittent bursts of 
metabolic activity inhabiting solid caseous material and a small population of bacilli 
within the acidic environment around the areas of active inflammation or necrosis.  The 
growth characteristics within each lesion result in differing susceptibility to specific 
antituberculosis agents (25) and simulating such varying populations in vitro is very 
challenging. Only a few studies have been reported so far where different metabolic 
populations of MTB growing under acidic conditions and under anaeroboic/hypoxic 
conditions have been subjected to antituberculosis drug treatment using in vitro PK/PD 
models (104). 
 
 
Pharmacokinetic Factors 
 
Drug distribution is technically challenging to simulate in vitro. Using complex in 
vitro setups, one can approximate the in vivo elimination process of the drug, but the 
model may not truly represent the in vivo drug distribution. Plasma protein binding of the 
antibiotic is absent in in vitro models and needs to be accounted for. Thus, free drug 
concentrations relevant to the site of infection must be simulated. Although this is 
feasible, protein binding in vivo is a dynamic process and can be altered due to co-
existing disease conditions or the presence of other drugs which is challenging to 
simulate in vitro. 
 
 
Summary 
 
In vitro experiments are useful in evaluating the direct interaction between 
antituberculosis agents and Mycobacterium tuberculosis, which aids in the selection of 
candidate compounds during antituberculosis drug development. Utilizing in vivo drug 
clearance profiles from animal and/or human studies and simulating them in an in vitro 
PK/PD model allows the in depth characterization of antimycobacterial activity of new 
and existing anti-TB agents by generating time-kill data. These data capture the dynamic 
interplay between mycobacterial growth and changing drug concentration as encountered 
during prolonged drug therapy.  
 
Pharmacokinetic parameters such as protein binding and drug distribution play an 
important role when extrapolating results from an in vitro experiment to humans or 
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animals. While MIC and MBC are most commonly used in vitro pharmacodynamic 
parameters, AUC/MIC, Cmax/MIC and T >MIC are the three most commonly used PK/PD 
indices to evaluate antimycobacterial effects of antituberculosis agents. 
 
On the basis of drug exposure and bacterial concentration in vitro PK/PD models 
for antituberculosis agents can be classified into static models and dynamic models. 
While static models evaluate how a bacterial culture responds to a constant environment 
with a fixed antibiotic exposure, dynamic models utilize time-kill curves, which follow 
the mycobacterial killing and growth as a function of both time as well as antibiotic 
concentration. In vitro models can serve as useful tools to study postantibiotic effect, the 
emergence of resistance and help identify novel drug combinations to treat drug resistant 
mycobacterial strains.  
 
PK/PD modeling and simulation techniques allow characterizing the time course 
of the effect intensity of an antibiotic resulting from a certain dosing regimen and have 
been applied with success to antituberculosis agents for evaluating their initial rate of the 
bacterial killing and the re-growth of mycobacteria and to obtain a relevant PK/PD index 
which correlates with therapeutic outcome. 
 
In spite of the potential advantages, in vitro models are obvious simplifications of 
in vivo scenarios and therefore come with certain drawbacks such as absence of immune 
response, divergent physiological conditions in vivo and differences in growth conditions 
of mycobacteria in vitro versus in vivo. Since these in vitro models have benefits of 
reduced cost, flexibility and adaptability, they are often used to guide the early drug 
development process, to minimize lengthy experiments for testing antituberculosis 
activity in vivo, and may help clinicians and researchers combat and treat tuberculosis 
patients, producing ultimately improved treatment outcomes. 
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CHAPTER 2. RESEARCH HYPOTHESIS 
 
 
Lead optimization is a complex process of refining the chemical structure of a 
screen lead to improve its drug-like properties in order to successfully produce a 
development candidate. Using an iterative approach the knowledge gained at each stage 
is used to further optimize each new cycle. In an early development phase, this tends to 
be chemistry intensive and the optimization is carried out after evaluating the 
pharmacological, biopharmaceutic and pharmacokinetic profile using a variety of in vitro 
and in vivo methods. One of the tasks towards achieving this goal is to develop a 
comprehensive absorption, distribution, metabolism and elimination (ADME) package 
which includes data on absorption/permeability, mechanisms of clearance, oral 
bioavailability, interaction with CYP enzymes to evaluate metabolic stability, and plasma 
protein binding (135). For an antituberculosis drug in particular, the effectiveness 
depends upon its ability to reach the site of infection in a sufficiently high unbound 
concentration and to remain at the site of infection for a sufficiently long period of time. 
Along with that, the compound should possess the ability to penetrate the bacterial cell 
wall to achieve sufficient intracellular concentrations. In order to target the primary phase 
of TB infection, the drug should also be able to penetrate into macrophages. Once it 
reaches its target, the compound should have good intrinsic activity towards its target to 
achieve the required antimicrobial effect. 
 
 I hypothesized that designing a screening paradigm involving ADME and drug 
uptake assays into MTB as well as macrophages would facilitate the identification and 
characterization of lead compounds specific for antituberculosis therapy. To address this 
hypothesis, I utilized a series of existing in vivo and in vitro assays (Chapter 3) such as 
plasma protein binding, microsomal metabolic stability and in vivo pharmacokinetics, and 
developed novel drug uptake assays into M. bovis BCG and J774 murine macrophage to 
identify and characterize lead molecules from a novel spectinamide series of 
antituberculosis agents.     
 
PK/PD concepts have recently been applied more widely in the drug 
development, lending statistical and causal support to the evaluation of the dose-response 
relationship and are advocated as a means of improving development efficiency (136). 
For rapid antituberculosis drug development in vitro PK/PD models are useful in 
evaluating the direct interaction between the drug and the bacteria, thereby guiding the 
selection of candidate compounds and the optimization of their dosing regimens. 
Utilizing in vivo drug-clearance profiles from animal studies and simulating them in an in 
vitro PK/PD model allows the in-depth characterization of antibiotic activity of new and 
existing antibacterials by generating time–kill data. These data capture the dynamic 
interplay between mycobacterial growth and changing drug concentration as encountered 
during prolonged drug therapy in vivo (137).  
 
Following the selection of a lead molecule, I hypothesized that simulating the in 
vivo pharmacokinetic profile at different dosing regimens in an in vitro PK/PD system 
helps in characterizing the dose-response relationship which further facilitates rational 
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dose selection for the in vivo efficacy study in animal models infected with TB. To 
address this hypothesis, we determined the time course of bacterial kill rates for dosing 
regimens of a spectinamide lead compound, Lee1445 in the in vitro PK/PD model 
(Chapter 4). Based on this data, we developed an in silico pharmacodynamic model for 
describing the Lee1445 mediated bacterial kill and applied this in silico model to predict 
the bactericidal effect of Lee1445 at different, untested dosing regimens by numerical 
simulation experiments. Based on the predictions, we suggested an optimal dosing 
regimen that should be tested in the in vivo efficacy study in order to maximize the 
efficacy in terms of reduction of mycobacterial load in the animal.      
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CHAPTER 3. PHARMACOKINETIC EVALUATION OF SPECTINAMIDES 
 
 
Introduction 
 
TB is a contagious and airborne disease caused by Mycobacterium tuberculosis. 
According to the WHO global tuberculosis control report of 2010, approximately 1.7 
million people died from TB in 2009 with a vast majority of deaths occurring in 
developing countries. There were 9.4 million new TB cases in 2009 of which 1.1 million 
cases were co-infected with HIV. The highest rates of MDR-TB so far have been 
reported in 2010, where patients failed to respond to the standard first-line drugs. About 
58 countries reported XDR-TB which is resistance to the second-line agents on top of 
MDR-TB (1).  
 
In the past decade there has been a reawakening of TB drug research and 
development was spurred by an urgent need to prevent the rising cases of this disease 
globally and develop new and more effective treatments against both drug sensitive and 
resistant strains. The primary goals are to shorten and simplify the treatment of active TB, 
provide safer and more efficacious treatments for drug-resistant TB, simplify treatment of 
TB-HIV co-infections by eliminating unwanted drug-drug interactions, and shorten 
treatment for latent TB infection (138). 
 
From a biopharmaceutic and pharmacokinetic standpoint, an ideal TB drug should 
possess high oral bioavailability, since oral administration is the route of choice for better 
patient compliance, indicating that the compound should have good aqueous solubility 
and gastrointestinal permeability. In order to allow lesser frequency of dosing, it should 
possess a longer elimination half-life (5). To target the primary phase of TB, the drug 
should be able to penetrate into macrophages and also into the bacterial envelope 
assuming the drug target is located intracellularly. In an effort to develop more potent 
drugs for the treatment of TB, a novel class of antituberculosis agents called 
spectinamides, with promising in vitro activity against MTB, has been recently 
characterized by our group.  
 
Spectinamides are novel amide derivatives of the antibiotic spectinomycin and 
have emerged as a new class of agents to treat tuberculosis. These agents showed potent 
in vitro activity against Mycobacterium tuberculosis compared to spectinomycin. In a 
preliminary in vivo study in IFN-γ knockout mice, spectinamide Lee1329 reduced the 
lung bacillary load of TB comparable to streptomycin. The main objective of the work 
summarized in this chapter is to characterize the biopharmaceutic and pharmacokinetic 
properties of selected spectinamides and develop a rational screening paradigm which 
will further improve the early drug development process. This will enable us in iteratively 
optimizing these molecules via structural modification to further improve their PK 
properties.  
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Materials and Methods 
 
  
Chemicals and Reagents 
 
All tested spectinamides were synthesized in the laboratory of Dr. R.E. Lee at St. 
Jude Children’s Research Hospital, Memphis, TN, including Lee1329 (3’-dihydro-3’-
deoxy-4(R)-(pyridin-2-yl) acetylamino spectinomycin), Lee1443 (3’-dihydro-3’-deoxy-
4(R)-(thiazol-4-yl) acetylamino spectinomycin), Lee1445 (3’-dihydro-3’-deoxy-4(R)-(5-
fluoropyridin-2-yl) acetylamino spectinomycin), Lee1465 (3’-dihydro-3’-deoxy-4(R)-
(benzooxazol-2-yl) acetylamino spectinomycin), Lee1540 (3’-Dihydro-3’-deoxy-4(R)- 
(2-((4-(trifluoromethoxy) phenyl) amino) thiazol-4-yl) acetylamino spectinomycin), and 
Lee1544 (3’-Dihydro-3’-deoxy-4(R)-(4-chloropyridin-2-yl) acetylamino spectinomycin) 
(Figure 3-1). Acetonitrile, Methanol, HPLC grade water, formic acid and ammonium 
formate were purchased from Fisher Scientific (Pittsburgh, PA). Drug free rat plasma was 
purchased from Aleken Biologicals (Nash, TX). 
 
 
Caco-2 Permeability Assay  
 
Caco-2 permeability data was obtained from the high throughput screening 
laboratory in the department of Chemical Biology and Therapeutics, St. Jude Children’s 
Hospital, Memphis, TN. This assay was performed in the 96-well Transwell system. 
Caco-2 cells were maintained at 37 ⁰C in a humidified incubator with an atmosphere of 
5% CO2. The cells were cultured in minimum essential medium (MEM) containing 20% 
fetal bovine serum (FBS) in 75 cm2 flasks, 100 units/ml of penicillin, and 100 μg/ml of 
streptomycin. The Caco-2 cells were seeded onto inserts of a 96-well plate at a density of 
0.165×105 cells/insert and cultured in the MEM containing 10% FBS for 7 days. Each 
cultured monolayer on the 96-well plate was washed twice with HBSS/HEPES (10 mM, 
pH 7.4). The permeability assay was initiated by the addition of each compound solution 
(50 μmol/L) into inserts (apical side, A) or receivers (basolateral side, B). The Caco-2 
cell monolayers were incubated for 2 h at 37 ⁰C. Fractions were collected from receivers 
(if apical to basal permeability) or inserts (if basal to apical permeability), and 
concentrations were assessed by UPLC/MS (Waters; Milford, MA). All compounds were 
tested in triplicates. The A→B (or B→A) apparent permeability coefficients (Papp, cm/s) 
of each compound were calculated using the equation, Papp=dQ/dt×1/AC0. The flux of a 
drug across the monolayer is dQ/dt (μmol/s). The initial drug concentration on the apical 
side is C0 (μmol/L). The surface area of the monolayer is A (cm2). 
 
 
In Vitro Microsomal Metabolic Stability 
 
In vitro microsomal metabolic stability of the compounds was assessed using 
pooled liver microsomal preparations (Cellzdirect, Austin, TX). Reactions were started 
by adding 25 μL of microsomal protein solution (10 mg/mL) to 25 μL of test compound 
(20 μM) and 200 μL of NADPH regenerating solution (1.3 mM NADP+, 3.3 mM 
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Figure 3-1. Chemical structures of spectinomycin, first generation 2-heteroaryl acetic acid amide analogs (Lee1329, Lee1443, 
Lee1445 and Lee1544), second generation fused ring analog (Lee1465) and second generation phenyl amino thiazole analog 
(Lee1540). 
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glucose-6-phosphate, 3.3 mM MgCl2 and 1 unit/mL glucose-6-phosphate dehydrogenase 
in pH 7.4 phosphate buffer solution). The reaction mixture was incubated at 37 ⁰C and 
samples were taken at 0, 5, 10, 15, 30, 45, 60 and 90 minutes respectively. A reaction 
mixture containing above mentioned composition but instead using deactivated 
microsomes was used as negative control and a nitrofuranylamide with known significant 
phase I metabolism Lee1341 was used as positive control. All the samples were analyzed 
using LC-MS/MS assay. Disappearance of the parent compound was monitored during 
the incubation period. The percentage of parent compound remaining intact was 
estimated by comparing analyte concentrations before and after incubation.  
 
 
Protein Binding 
 
Protein binding of the compounds was determined using equilibrium dialysis. 
Biologically relevant concentrations of test compound were prepared (low and high) in 
plasma. 200 μL of the plasma sample was placed in the central chamber and 350 μL of 
blank isotonic phosphate buffer, pH 7.4 was added to the peripheral chamber of a dialysis 
device (MW cutoff 6000-8000 D, RED® device, Pierce Biotechnology Inc, Rockford, 
IL). The chambers were covered with a seal and incubated at 37 ⁰C for four hours on a 
shaker set at 100 rpm. At the end of incubation, the volumes of plasma and recipient 
buffer were measured to identify and account for volume shift, if any. Aliquots of plasma 
and buffer were used to determine the drug concentration using an LC-MS/MS assay. 
The free fraction of the drug was calculated as ratio of the concentrations in the buffer 
and in plasma. 
 
 
Pharmacokinetic Studies 
 
Catheterized male Sprague-Dawley rats (jugular vein alone for oral study and 
jugular vein and femoral vein for intravenous study) weighing approximately 225 g were 
obtained from Harlan Bioscience (Indianapolis, IN). The animals were kept on a 12 hr 
light/dark cycle with food and water available ad libitum. Groups of rats (n = 4) received 
either an intravenous (IV) or oral dose of a test compound at a dose level of 10 mg/Kg or 
100 mg/Kg, respectively. For oral administration, the animals were fasted overnight and 
until 4 hours after administration of test compound. Serial blood samples (approx. 250 
μL) were collected pre-dose and at predetermined time points post-dose until 48 hours. 
Plasma was separated immediately by centrifugation (10,000 rpm for 10 min at 4 ⁰C) and 
stored at -80 ⁰C until analysis. Urine specimens were collected for a period of 48 hours 
following drug administration. The study protocol was approved by the institutional 
animal care and use committee of the University of Tennessee Health Science Center. 
 
 
Sample Preparation and LC-MS/MS Assay 
 
A calibration curve ranging from 3.9-5000 μg/L was constructed for each test 
compound by spiking the test compound into 50 μL of blank rat plasma. A structurally 
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similar analogue to the test compounds, Lee1369, was used as internal standard (IS) to all 
calibration standards and all plasma specimens. Plasma proteins were precipitated by the 
addition of four volumes of ice cold methanol containing IS. These samples were 
vortexed and kept on ice for 20 minutes. Following this, the samples were centrifuged at 
10,000 rpm for 10 minutes at 4 ⁰C and the supernatants were diluted if necessary and 
injected into LC-MS/MS system for analysis. Chromatographic separations were carried 
out using a Shimadzu liquid chromatography system (Shimadzu Corporation, USA) 
consisting of two pumps, online degasser, system controller and a CTC Leap auto 
sampler (Leap Technologies, Carrboro, NC). A gradient of methanol and 10 mM 
ammonium acetate at pH 3.5 was used at a flow rate of 0.4 mL/min. A Phenomenex® 
Luna 3μ HILIC, 100 x 4.6 mm column (Phenomenex, Torrance, CA) protected with a 
guard column was used for the separation. 10 μL of sample was injected onto the column 
and the elute was led directly into an API 3000 triple-quadrupole mass spectrometer 
(Applied Biosystems ABI/MDS-Sciex, Foster City, CA) equipped with an electrospray 
ion source. The instrument was operated in the positive ion mode with nebulizer gas 
(NEB) at 7 psi, curtain gas (CUR) at 8 psi, collision gas (CAD) at 10 psi, ion spray 
voltage (IS) at +4000 V and temperature (TEM) at 500 ⁰C. The resulting multiple 
reaction monitoring chromatograms were used for quantification using the Analyst 
software version 1.4.1 (Applied Biosystems ABI/MDS-Sciex, Foster City, CA). 
 
 
Pharmacokinetic Data Analysis  
 
Plasma concentration-time data obtained from oral and intravenous administration 
were analyzed by non-compartmental analysis. Also, a two compartment open model 
with bolus input and first order output was used to analyze the IV plasma concentration-
time data. The area under the plasma concentration-time curve from time zero to infinity 
(AUCinf) was calculated by the trapezoidal rule with extrapolation to time infinity. Mean 
residence time (MRT), the average amount of time a particle remains in a compartment 
of system was calculated for IV dose using MRT=AUMCinf/AUCinf where AUMCinf is 
the area under the moment curve when the concentration-time curve is extrapolated to 
infinity. The systemic clearance (CL) was calculated using the equation 
CL=Doseiv/AUCinf, iv, where Doseiv and AUCinf, iv are the IV dose and corresponding area 
under the plasma concentration-time curve from time 0 to infinity, respectively. An 
estimate of volume of distribution at steady state (Vss) was obtained from IV data using 
Vss=MRT*CL. Oral bioavailability (F) was calculated using F = (AUCinf, oral*Doseiv)/ 
(AUCinf, iv*Doseoral), where Doseoral, Doseiv, AUCinf, iv, and AUCinf, oral are the oral and 
IV doses and the corresponding areas under the plasma concentration-time curves from 
time zero to infinity, respectively. Urinary excretion parameters were calculated from the 
cumulative dose excreted unchanged in urine and the fraction unbound in plasma (fup). 
Glomerular filtration rate (GFR) and hepatic blood flow (Qh) were taken from the 
physiologic parameters published by Davies et al. (139). The fraction (fe) of the test 
compound excreted in urine was calculated as the cumulative amount of dose excreted 
unchanged in urine divided by the dose of the test compound administered. Renal 
clearance (CLr) values were determined from the total plasma CL and the fraction 
excreted in urine using fe*CLtotal. The net process a drug undergoes in the kidney can be 
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evaluated using excretion ratio (Eratio). This was calculated using CLr/(fup*GFR). Non-
renal clearance (CLnr) was calculated using CLtotal - CLr and the hepatic extraction ratio 
was calculated using CLnr/Qh. 
 
 
Drug Uptake into M. bovis BCG 
 
To study the uptake of spectinamide series of anti-tuberculosis agents into M. 
bovis BCG, bacterial cultures were grown in Middlebrook 7H9 medium (Becton 
Dickinson, Sparks, MD) with 10% albumin dextrose complex and 0.1% v/v Tween 80 to 
late log phase (OD600 = 0.75). These cultures were concentrated following a series of 
centrifugation steps to obtain a final cell density of approximately 1011 cells/mL. 
Concentrated culture suspension (1 mL) was added to pre-weighed centrifuge tubes. To 
this suspension, concentrated drug stock was added to obtain a final drug concentration of 
25 µg/mL and was incubated at 37 ⁰C for 4 hours. Following incubation, the suspension 
was centrifuged and the supernatant discarded. The cell pellet was washed thrice with 
DPBS (pH 7.0) and resuspended with 0.8 mL of sterile distilled water. This was bead 
beat using 0.1 mm glass beads three times (10 cycles of 10 seconds each time). The cell 
lysate was then sterile filtered and analyzed for drug content using a liquid 
chromatography-tandem mass spectrometric (LC-MS/MS) assay.  
 
 
Drug Uptake into Murine Macrophages 
 
To study the uptake of spectinamide antibiotics into murine macrophages, J774 
cells were grown to confluence in Dulbecco's Modified Eagle's Medium with 10% fetal 
bovine serum (ATCC, Manassas, VA) in tissue culture flasks maintained at 37 ⁰C in 5% 
CO2 incubator. These adhered cells were then scraped using a teflon cell scraper attached 
to a rubber policeman following aspiration of old media and addition of fresh media. The 
cells were counted after they were stained with tryphan blue using a hemocytometer on 
inverted microscope. The cell density was adjusted to 4 x 105 cells/mL using fresh media. 
The cell suspension was then added to new tissue culture flasks and was kept overnight to 
allow the cells to adhere. Media containing a final drug concentration of 25 µg/mL was 
added to these flasks following aspiration of old media and incubated for 24 h at 37 ⁰C in 
a 5% CO2 incubator. Following incubation the cells were washed thrice with DPBS (pH 
7.0). These cells were then scraped and resuspended in 0.6 mL sterile distilled water and 
were subjected to lysis using a bead beater (0.1 mm glass beads, three repeats of 10 
cycles of 10 seconds each). The cell lysate was then sterile filtered and analyzed for drug 
content using a liquid chromatography-tandem mass spectrometric (LC-MS/MS) assay.  
 
Cell cytotoxicity was studied for a range of drug concentrations (1.56 µg/mL to 
200 µg/mL) using the MTT cell proliferation assay (ATCC, Manassas, VA). 100 µl of 
each of these concentrations were added in triplicate in a 96 well plate and to each of 
these wells 100 µl of media containing J774 cells was added so that each well 
approximately has 103 to105 cells/well. A well containing cells without addition of drug 
was used as a control. These cells were incubated for 24 hours and 20 µl of MTT reagent 
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was added to each of these wells. These cells were incubated for 4 hours until a purple 
precipitate was visible. 100 µl of detergent reagent to each of these wells and was left at 
room temperature in the dark for 2 hours. Following this, absorbance at 570 nm was 
recorded and the ratio of absorbance of drug treated cells to untreated control was 
calculated which was converted to percentage activity or cell viability. 
 
 
Results and Discussion 
 
 
LC-MS/MS Assay Performance 
 
Linearity and Calibration Standards 
 
The peak area ratios of analyte to IS were linear over a concentration range of 3.9-
5000 µg/L for spectinamides. The best fit for the calibration curve was achieved by a 
linear equation of y = mx + c and a 1/x2 weighting factor with minimum of residuals and 
regression coefficients >0.992 to 0.998.  
 
Specificity and Selectivity 
 
Chromatograms of control drug free plasma contained no co-eluting peaks of 
analyte area at the lowest limit of quantitation (LLOQ) level and no co-eluting  
peaks >5% of the area of IS. There was no cross interference between the analytes. The 
retention times of analyte and IS showed low variability with a relative standard 
deviation (RSD) well within the acceptable limit of 5%. 
 
Limit of Detection (LOD) and Lowest Limit of Quantitation (LOQ) 
 
The LOD for which the analyte gave a signal-to-noise ratio (S/N) of ≥ 3 was 
determined as 1.95 µg/L concentration. The LLOQ, the lowest concentration in the 
standard curve which can be measured with acceptable accuracy and precision for 
spectinamides from normal rat plasma, was established as 3.9 µg/L, with an exception of 
Lee1443 (LLOQ of 7.8 µg/L). 
 
 
Biopharmaceutical Properties 
 
All active spectinamides have molecular weights below 500 Da except for 
Lee1540 (Table 3-1). While logP refers to the logarithm of the Partition Coefficient, P, 
which is defined as the ratio of concentration of neutral species in octanol divided by the 
concentration of neutral species in water, logD refers to the logarithm of the distribution 
coefficient, D, which is defined as the ratio of concentrations of all species i.e., neutral 
and ionized, present in octanol divided by the concentration of all species in water. In 
silico calculated logP (CLogP) values (CS ChemDraw, CambridgeSoft Corporation, MA) 
as well as calculated logD values (MarvinView, ChemAxon Ltd., Hungary) suggested
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Table 3-1. Physicochemical and biopharmaceutical properties of spectinamides. 
 
 
Notes: MW: Molecular weight 
 CLogP: Calculated logarithm of partition coefficient 
 LogD: Calculated logarithm of distribution coefficient at pH 7.0 
tPSA: Topological polar surface area 
 Papp: Apparent permeability coefficient 
 B/A: Basolateral to apical 
 A/B: Apical to basolateral 
  
Molecule MW  (Da) CLogP 
LogD  
pH 7.0 
tPSA 
(Å2) 
Caco-2 permeability 
Papp  
(A/B)  
(nm/s) 
Papp  
(B/A) 
(nm/s) 
Efflux  
ratio 
B2A/A2B 
Spectinomycin 332.3 -2.87 -3.93 129.5 224.5 176.1 0.78 
Lee1329 452.5 -3.31 -4.14 153.9 46.4 76.6 1.65 
Lee1443 458.5 -3.47 -4.26 153.9 89.6 115.0 1.28 
Lee1445 470.5 -3.08 -4.00 153.9 145.0 149.5 1.03 
Lee1465 492.5 -2.54 -3.59 163.1 225.0 153.8 0.68 
Lee1540 633.6 0.1 -0.71 175.2 133.4 142.5 1.07 
Lee1544 486.9 -2.51 -3.54 153.9 146.8 142.0 0.97 
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that these molecules are highly hydrophilic with the most lipophilic being Lee1540. All 
the active spectinamides were easily soluble in water (at least 50 mg/mL). Due to 
insufficient compound, the exact solubility has not been reported.  
 
The topological polar surface area (tPSA) is a physicochemical descriptor that is 
used in predicting permeability and a PSA ≤ 140 Å2 indicates good gastrointestinal 
permeability leading to an oral bioavailability anywhere between 20-100% (140). 
However, all the active spectinamides synthesized so far had a PSA > 140 Å2 suggesting 
poor permeability. This was evident in the Caco-2 permeability assay which is often used 
as a surrogate for human intestinal permeability. All the spectinamides showed very low 
apparent permeability in the range of nm/s. All these results suggest that spectinamides 
have poor permeability and hence without any chemical modification would lead to poor 
oral bioavailability. However, they all can be administered via the intravenous route.   
 
 
In Vitro Microsomal Metabolic Stability 
 
Metabolic stability is an important property of a drug candidate since it affects the 
PK parameters such as hepatic clearance, half-life as well as bioavailability. 
Spectinomycin; spectinamides Lee1329, Lee1443, and Lee1445; nitrofuranylamide 
Lee1341 as positive control, with known significant metabolism by microsomal fraction, 
(unpublished report); and deactivated microsomes as negative control were studied in this 
assay. Spectinomycin and spectinamides were found to be metabolically stable to 
enzymes present in the microsomal fraction i.e., essentially CYP family of enzymes. 
After 90 min incubation in the presence of NADPH and rat liver microsomal fraction, the 
parent compound remaining was found to be between 80 to 100% (Figure 3-2) indicating 
that the spectinamides do not undergo significant oxidation, reduction or hydrolysis 
catalyzed by Phase I enzymes. This also suggests that following oral administration, there 
will likely not be any significant first pass effect. This result indicates that the most likely 
route of elimination following i.v. administration would be via the renal route as seen in 
the case of spectinomycin where nearly 75% of the drug was eliminated unchanged in the 
urine (42). Table 3-2 shows the metabolic half-life of spectinamides in the presence of 
mouse and human liver microsomal fraction.  
 
 
Protein Binding 
 
Plasma protein binding can be an important factor in determining drug 
distribution, metabolism and elimination. Drugs usually are non-specifically adsorbed 
onto protein surfaces or reversibly bound at specific sites. Therefore, a drug in circulation 
will exist in two forms, bound and unbound and assuming that the binding is reversible, 
these two forms will be in equilibrium. It is only the unbound drug can diffuse across cell 
membranes and cause a pharmacological effect. Hence it is important to evaluate the 
extent of plasma protein binding. Apart from Lee1540, spectinamides in general showed 
low to intermediate protein binding in human, rat and mouse plasma. Lee1540 was 90%-
100% bound to plasma proteins which can be attributed to its improved lipophilicity 
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Figure 3-2. In vitro rat liver microsomal metabolic stability of spectinamides. 
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Table 3-2. Metabolic half-life of spectinamides in presence of human and mouse liver 
microsomes. 
 
Compound Half-life (hr) human 
Half-life (hr) 
mouse 
Spectinomycin 2.48 >10 
Lee1329 8.59 >10 
Lee1443 18.51 5.59 
Lee1445 5.24 6.89 
Lee1465 22.07 13.08 
Lee1540 >50 >50 
Lee1544 2.58 1.51 
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compared to other spectinamides (CLogP of 0.1). Table 3-3 summarizes the extent of 
plasma protein binding of spectinamides in human, rat and mouse plasma. This result 
suggests that plasma protein binding does not limit the drug concentrations from reaching 
therapeutic levels intracellularly for its efficacy. 
 
 
Pharmacokinetics 
 
First Generation Molecules 
 
Lee1329, Lee1443, Lee1445 and Lee1544 are 2-heteroaryl acetic acid amide 
analogs of spectinomycin and belong to the first generation of spectinamides that showed 
potent in vitro activity against MTB. Following intravenous administration of 10 mg/Kg 
in rats, all molecules except Lee1443 showed similar bi-exponential concentration-time 
profiles with distinct distribution and elimination phases (Figures 3-3, 3-4 and 3-5). The 
pharmacokinetic parameters are shown in Table 3-4. Due to the lack of a very sensitive 
analytical method for Lee1443, concentrations below 7.8 µg/L could not be quantified. 
Since Lee1443 concentrations beyond 4 hours fell below this LLOQ of 7.8 µg/L, the bi-
exponential PK profile could not be captured for this molecule. Hence a mono-
exponential concentration-time profile was fit to the available data.  
 
All four compounds showed a similar alpha half-life of 0.30 to 0.35 hr. Lee1329, 
Lee1445 and Lee1544 showed a prolonged beta half-life ranging from 6.6 to 21 hr. The 
beta phase, however, contributed only minimally to the overall systemic exposure (AUC) 
with its plasma concentrations being 100 to1000 fold lower than the peak concentrations. 
This behavior is common for aminoglycosides and many other amines and is likely 
related to slow leakage of compound from deep tissue compartments. The underlying 
mechanism is likely lysosomal trapping and/or complexation with membrane 
phospholipids (141).  
 
First generation spectinamides showed a steady state volume of distribution 
ranging from 0.46 to 1.15 L/Kg  and the area under the curve ranged from 11.3 to 18 
mg.hr/L. They exhibited a mean residence time of 0.52-1.55 hours and a mean systemic 
clearance of 0.56-0.89 L/hr/Kg. The percent dose excreted unchanged by the kidneys (fe) 
ranged from 46% to a 100%. The excretion ratio (Eratio) for all these compounds was 
greater than one indicating active secretion as the net urinary elimination process.  
 
Following 100 mg/kg oral administration in rats, Lee1329 and Lee1544 showed 
similar bi-exponential concentration-time profiles (Figures 3-3 and 3-5). However, they 
exhibited poor oral bioavailability of 4.0 and 3.2 % respectively (Table 3-5). These 
molecules have limited permeability leading to poor oral bioavailability. Hence 
improving lipophilicity and decreasing polar surface area without compromising on the 
solubility might be a strategy to enhance the oral bioavailability of these agents. 
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Table 3-3. Protein binding of spectinamides in human, rat and mouse plasma. 
 
Compound %Bound human 
%Bound 
rat 
%Bound 
mouse 
Spectinomycin 51.6 - 52.6 
Lee1329 62.1 28.5 36.9 
Lee1443 52.4 13.0 41.6 
Lee1445 45.8 28.0 38.0 
Lee1465 42.9 44.0 50.0 
Lee1540 96.9 90.0 100.0 
Lee1544 56.4 15.0 39.8 
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A) 
 
 
 
B)  
 
 
 
Figure 3-3. Measured plasma concentration-time profiles (mean ± SD) after 
intravenous (10 mg/Kg, Panel A) or oral (100 mg/Kg, Panel B) administration of 
Lee1329 in rats. Dashed line denotes LLOQ. 
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A) 
 
 
 
B) 
 
 
 
Figure 3-4. Measured plasma concentration-time profiles (mean ± SD) after 10 mg/Kg 
intravenous administration of Lee1443 (Panel A) and Lee1445 (Panel B) in rats. Dashed 
line denotes LLOQ. 
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A) 
 
 
 
B) 
 
 
 
Figure 3-5. Measured plasma concentration-time profiles (mean ± SD) after 
intravenous (10 mg/Kg, Panel A) or oral (100 mg/Kg, Panel B) administration of 
Lee1544 in rats. Dashed line denotes LLOQ.   
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Table 3-4. Pharmacokinetic parameters of spectinamides following intravenous administration (10 mg/Kg). 
 
 
Notes: Cmax: Peak or maximum concentration 
 AUCinf: Area under the curve from time zero extrapolated to infinity 
 CL: Total body clearance 
 Vd: Volume of distribution  
 t1/2: Half-life 
 t1/2α: Half-life associated with the macro rate constant α 
 t1/2β: Half-life associated with the macro rate constant β 
MRT: Mean residence time 
fe: Fraction of drug eliminated unchanged in the urine 
 Eratio: Excretion ratio 
 
 
Compound 
Cmax AUCinf CL Vd t1/2 t1/2α t1/2β MRT 
fe Eratio (mg/L) (mg.hr/L) (L/hr/Kg) (L/Kg) (hr) (hr) (hr) (hr) 
Lee1329 21.6 ± 1.3 13.8 ± 1.4 0.74 ± 0.08 1.15 ± 0.14  0.48 ± 0.04 0.34 ± 0.05 15.3 ± 3.6 1.55 ± 0.05 0.46 ± 0.04 1.4 
Lee1443 13.0 ± 0.7  11.3 ± 0.8  0.89 ± 0.06 0.46 ± 0.05 0.44 ± 0.01 0.35 ± 0.05 - 0.52 ± 0.06 0.87 ± 0.11 2.9 
Lee1445 20.9 ± 1.2 18.0 ± 1.6  0.56 ± 0.05 1.03 ± 0.13 0.43 ± 0.06 0.32 ± 0.03 21.0 ± 7.8 0.57 ± 0.04 1.08 ± 0.09 2.5 
Lee1465 24.2 ±  5.2 19.9 ± 4.4 0.53 ± 0.15 0.36 ± 0.15 0.54 ± 0.07 0.30 ± 0.03 14.2 ± 7.4 0.68 ± 0.16 0.99 ± 0.06  2.1 
Lee1540 35.8 ± 11.2 31.7 ± 10.8  0.36 ± 0.16 0.27 ± 0.15  0.62 ± 0.09 0.31 ± 0.02 12.5 ± 6.1 0.73 ± 0.28 0.06 ± 0.04  0.49 
Lee1544 22.4 ± 2.4 12.9 ± 1.4  0.78 ± 0.08 0.80 ± 0.47  0.56 ± 0.08 0.30 ± 0.03 6.6 ± 7.3 1.02 ± 0.59 0.62 ± 0.25 1.5 
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Table 3-5. Pharmacokinetic parameters of spectinamides following oral 
administration (100 mg/Kg). 
 
Compound 
Cmax Tmax AUCinf F 
(mg/L) (hr) (mg.hr/L) (%) 
Lee1329 1.46 ± 1.24 0.69 ± 0.59 5.26 ± 3.19 4.0 
Lee1465 1.38 ± 0.37 0.56 ± 0.24 2.36 ± 0.64 1.2 
Lee1540 1.94 ± 0.95 0.58 ± 0.14 2.87 ± 0.83 0.9 
Lee1544 2.14 ± 1.56 0.75 ± 0.47 4.12 ± 0.82 3.2 
 
Notes: Cmax: Peak or maximum concentration 
 Tmax: Time to reach peak concentration 
 AUCinf: Area under the curve from time zero extrapolated to infinity 
 F: Absolute bioavailability 
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Second Generation Molecules 
 
Fused ring analog Lee1465 and phenyl amino thiazole analog Lee1540 belong to 
the second generation of spectinamides that were found to be active in the in vitro assays 
against MTB.  Following i.v. administration (Figure 3-6), Lee1465 had a mean systemic 
clearance of 0.53 L/hr/Kg and exhibited a steady state volume of distribution of 0.36 
L/Kg. It is only 40% bound to plasma proteins and has a good microsomal metabolic 
stability. Therefore most of the dose was eliminated unchanged by the kidneys (fe 0.99). 
Thus, renal excretion is the major elimination pathway for this molecule. The excretion 
ratio (Eratio) of Lee1465 is 2.1 suggesting active secretion as the net urinary elimination 
process. In contrast, Lee1540 is characterized by a high plasma protein binding of 90%-
100%, probably a reflection of its increased lipophilicity. Following intravenous 
administration (Figure 3-7), the mean systemic clearance of Lee1540 (0.36 L/hr/Kg) is 
low when compared to the other compounds in the series and it has a relatively low 
steady state volume of distribution of 0.27 L/Kg indicative of its poor tissue permeability. 
The fraction of dose excreted unchanged by the kidneys (fe) is 6%. Thus, non-renal 
elimination seems to be the major elimination pathway for Lee1540. Since microsomal 
metabolic stability studies suggest high stability towards liver microsomes from mice, 
rats and humans, the elimination of Lee1540 is likely related to phase II metabolism 
and/or biliary excretion. Also, Lee1540 has a MW of 633.6 Da and the likelihood of 
phase II metabolism increases with MW for compounds greater than 500 Da.  
 
Following oral administration, both Lee1465 and Lee1540 showed very poor oral 
bioavailability (1.2 and 0.9 % respectively) in spite of their improved lipophilicity in 
relation to other molecules in the series. This can be attributed to the fact that the 
chemical modifications increased the polar surface area of the molecules making them 
even more poorly permeable. Based on the bioavailability findings, all these agents can 
be administered via intravenous route until newer compounds with much better oral 
bioavailability are discovered.  
 
 
Drug Uptake into M. bovis BCG 
 
Spectinamides and spectinomycin are structurally similar molecules. However, 
first generation spectinamides are approximately 30-60 times more potent than 
spectinomycin in the in vitro MIC assays (Figure 3-1). Interestingly, the IC50 values for 
the antiribosomal activity in a cell free translation assay using M. smegmatis ribosomes 
did not significantly differ between the spectinamides and spectinomycin indicating that 
all these have similar intrinsic activity at the target site on the ribosome. In order to 
evaluate the differences in their potencies, drug uptake into mycobacterium was studied. 
After incubating the M. bovis BCG cells with different molecules for a period of 4 hours, 
the total drug taken up into the cells was estimated. The results of this assay are shown in 
Table 3-6. 
 
Compared to spectinomycin, spectinamides Lee1329 and Lee1445 showed 
approximately 4 times higher uptake into the mycobacterial cells. Since these molecules 
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A) 
 
 
 
B) 
 
 
 
Figure 3-6. Measured plasma concentration-time profiles (mean ± SD) after 
intravenous (10 mg/Kg, Panel A) or oral (100 mg/Kg, Panel B) administration of 
Lee1465 in rats. Dashed line denotes LLOQ. 
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 A) 
 
 
 
B) 
 
 
 
Figure 3-7. Measured plasma concentration-time profiles (mean ± SD) after 
intravenous (10 mg/Kg, Panel A) or oral (100 mg/Kg, Panel B) administration of 
Lee1540 in rats. Dashed line denotes LLOQ.  
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Table 3-6. Drug uptake into M. bovis BCG. 
 
Molecule Amount (ng)/ weight of cells (gm) %CV 
Ratio w.r.t. 
spectinomycin 
Spectinomycin 650 5 - 
Lee1329 2548 3.6 3.9 
Lee1445 2412 3.6 3.7 
 
Note: CV: Coefficient of variation  
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have similar solubility, lipophilicity, and tissue permeability, it was hypothesized that 
some active efflux pumps operate on the mycobacterial envelope that selectively pump 
out spectinomycin but not spectinamides thereby higher concentrations prevail for 
spectinamides. MIC studies performed by our collaborators at Universidad de Zaragoza, 
Spain, on efflux pump knockouts (KO-Rv1258c, KO-Rv1410c, KO-Rv2333c, KO-
Rv3065) of MTB showed that spectinamides Lee1329, Lee1445, and Lee1544 are not 
substrates to any of these efflux pumps while spectinomycin is a good substrate of efflux 
pump encoded by Rv1258c gene (unpublished report). The results of this study clearly 
answered some of the mechanistic aspects related to the potency of spectinamides in 
comparison to spectinomycin.  
 
 
Drug Uptake into Murine Macrophages 
 
 Before addition of the drug to the cells, cytotoxicity of spectinamides was 
assessed to ensure that drug treatment does not lyse the cells compromising the cell 
integrity. This was performed using an MTT cell proliferation assay for Lee1329, 
Lee1443, Lee1445 and streptomycin. The results of this assay are shown in Figure 3-8. 
These results indicate that spectinamides did not possess cytotoxicity towards J774 
murine macrophage cells even at very high concentrations of 200 µg/mL and hence 
ensures that the quantified drug would be from the intact macrophages and not from the 
macrophages lysed due to cell cytotoxicity. 
 
After being ingested by macrophages, the mycobacteria continue to multiply 
slowly with bacterial cell division occurring every 25 to 32 hours (142). Therefore it is 
important that the antimycobacterial agents reach the site where bacilli pervade within 
macrophages.  To evaluate this, spectinamides were incubated with murine macrophages 
and the drug uptake into macrophages was quantified. Streptomycin, a well established 
second line antituberculosis agent was used as a control. The results of this assay are 
shown in Table 3-7.  Compared to streptomycin, spectinamides Lee1329, Lee1443, and 
Lee1445 had 3 to 4 times better uptake into macrophages. These results suggest that 
sufficient intracellular concentrations of spectinamides can be attained within 
macrophages that can target the primary TB infection.  
 
 
Conclusion 
 
Identification and characterization of lead molecules from this spectinamide series 
of antituberculosis agents was achieved via a screening paradigm consisting of a series of 
existing in vivo and in vitro assays such as plasma protein binding, microsomal metabolic 
stability and in vivo pharmacokinetics, and novel drug uptake assays into M. bovis BCG 
and J774 murine macrophages. Spectinamides exhibited low to intermediate plasma 
protein binding and were found to be metabolically stable with the exception of Lee1540. 
Following intravenous administration, spectinamides were widely distributed (0.36 to 
1.15 L/Kg) with short half-lives (0.43 to 0.62 hr). Mean systemic clearance ranged 
between 0.36 to 0.89 L/hr/Kg with a significant fraction of drug eliminated unchanged in 
urine (0.46 to 1.0). Spectinamides except Lee1540 exhibited a renal excretion ratio  
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Figure 3-8. Cytotoxicity of spectinamides against J774 murine macrophages. 
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Table 3-7. Drug uptake into the J774 murine macrophage cell line. 
 
 
Note: CV: Coefficient of variation 
 
Molecule Amount (ng)/ weight of cells (gm) %CV 
Ratio w.r.t.  
streptomycin 
Streptomycin 10303 6.2 - 
Lee1329 29126 5.7 2.8 
Lee1443 38450 5.4 3.7 
Lee1445 44299 6.6 4.3 
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greater than 1 indicating filtration and active secretion as the net renal elimination 
process. In the uptake experiments, the spectinamides exhibited 3-4 times higher uptake 
into murine macrophages compared to streptomycin and showed nearly four times higher 
uptake into M. bovis BCG compared to spectinomycin, which may in part explain their 
increased activity compared to spectinomycin.  
 
Based on these properties, new generation of molecules can be synthesized 
retrospectively via structural modification to further improve their PK properties. In 
conclusion, we characterized the pharmacokinetic properties of key compounds in the 
spectinamide series and developed a screening paradigm that could be used for further 
optimization of leads specifically against MTB.  
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CHAPTER 4. PHARMACODYNAMIC EVALUATION AND DOSE 
OPTIMIZATION OF LEE1445 USING AN IN VITRO PK/PD MODEL 
 
 
Introduction 
 
The MIC is the most commonly used parameter to describe the efficacy of an 
antibacterial agent against a bacterial strain. However, it is not an optimal 
pharmacodynamic marker because it reflects only a point estimate of the effect and does 
not take the time course of the effect into account. The design of dosing schedules can 
further be optimized if they are based on models that take the whole time course of the 
PK/PD relationship, i.e., the time course of both the drug concentration and the bacterial 
concentration, into consideration (128). In vitro experiments are useful in evaluating such 
direct interaction between the drug and the bacteria, which enables the dose selection of 
candidate compounds. Utilizing in vivo drug clearance profiles from animal and/or 
human studies and simulating them in an in vitro PK/PD model allows the in-depth 
characterization of antimycobacterial activity of anti-TB agents by generating time-kill 
data. These data capture the dynamic interplay between mycobacterial growth and 
changing drug concentration as encountered during prolonged drug therapy (137).  
 
Spectinamides are a novel class of antituberculosis agents with potent in vitro 
antituberculosis activity that have been recently characterized by our group. On the basis 
of the pharmacokinetically guided screening paradigm, discussed in Chapter 2, which is 
designed to identify molecules with most suitable properties to become an effective 
antituberculosis agent, Lee1445 has emerged to be one such molecule from the class of 
spectinamides synthesized so far. Lee1445 was found to have potent in vitro activity 
against M. tuberculosis with an MIC of 0.4 µg/mL and an IC50 value of 0.58 µg/mL in 
the antiribosomal cell free translation assay using M. smegmatis ribosomes. From a PK 
perspective, it exhibited good metabolic stability with a half-life of 5.24 hr in the 
presence of human liver microsomes. The stability of Lee1445 in liver microsomal 
preparations indicates no involvement of the hepatic CYP enzyme system in the 
clearance of the compound. This absence of major hepatic CYP mediated metabolism 
increases the likelihood of compatibility with existing anti HIV medications which are 
mainly metabolized by the hepatic CYP enzyme system and are frequently co-
administered with anti-tuberculosis agents (143, 144). It has a protein binding of about 
28% in rat plasma suggesting that protein binding does not limit the drug concentrations 
from reaching therapeutic levels intracellularly for its efficacy. It showed approximately 
3 times higher uptake into mycobacteria compared to spectinomycin and about 4 times 
better uptake into murine macrophages compared to the existing second line agent 
streptomycin. Moreover, it did not possess any cell cytotoxicity against murine 
macrophages even at concentrations up to 200 µg/mL. On the down side, it showed a 
relatively short half-life of 0.43 hr with a clearance of 1.03 L/Kg after i.v. administration 
in rats suggesting the need for frequent dosing. Spectinamides in general showed poor 
oral bioavailability. A prodrug approach is currently being explored to overcome this 
limitation. However, given its potency against MTB, Lee1445 can be administered via 
i.v. route and can still serve as a valuable therapeutic option.  
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In the current chapter, we investigated the time course of bacterial kill of Lee1445 
using a previously reported in vitro PK/PD system (19). A novel and rapid method to 
quantify the bacterial counts based on adenosine triphosphate (ATP) measurements was 
developed. PK concentration-time profiles were simulated on the basis of the in vivo 
clearance of rats and the time-kill effect of different daily doses of Lee1445 were studied 
on the growing M. bovis BCG present in the PK/PD system. A mathematical model was 
fit to the time-kill data and in vitro PK/PD parameters were determined. Since the in vivo 
efficacy model of tuberculosis infection used in our development program was the 
gamma knock-out (GKO) mouse, a PK bridging study was performed in mice. 
Simulations for various dosing regimens were performed using the obtained mouse PK 
parameters and the in vitro PK/PD parameters, which were incorporated into a combined 
PK/PD model to predict the efficacy in terms of reduction of bacterial counts. Based on 
the results of the simulations, an optimal dose was chosen for the in vivo efficacy study. 
 
 
Materials and Methods 
 
 
Culture, Media, and Antibiotics  
 
Mycobacterium bovis BCG was grown in Middlebrook 7H9 broth (Becton 
Dickinson, Sparks, MD) supplemented with 10% albumin dextrose complex and 0.1% 
v/v Tween 80. The cultures were stored at -80 ⁰C in Middlebrook 7H9 broth. For each 
experiment, aliquots were thawed and incubated at 37 ⁰C in Middlebrook 7H9 broth for 4 
days. The test compound Lee1445 (3’-dihydro-3’-deoxy-4(R)-(5-fluoropyridin-2-yl) 
acetylamino spectinomycin) shown in Figure 3-1, was synthesized in the laboratory of 
Dr. R.E. Lee at the St. Jude Children’s Research Hospital, Memphis, TN. A stock 
solution of Lee1445 was prepared in methanol and stored at -80 ⁰C. Working solutions of 
the compound were prepared from the stock solution using distilled water. 
 
 
Minimum Inhibitory Concentration of Lee1445 
  
The MIC of Lee1445 was determined using the microbroth dilution method 
according to the CLSI guidelines (12) and was read by visual inspection. Two fold serial 
dilutions of Lee1445 in 100 μL of the Middlebrook 7H9 broth medium were prepared in 
round-bottomed micro liter plates (Nunc, Sigma-Aldrich, St. Louis, MO). An equivalent 
volume (100 μL) of broth containing ~105 CFU/mL bacteria was added to each well to 
give final concentration of Lee1445 starting at 200 mg/L and the plates were incubated 
aerobically at 37 ⁰C for 7 days. The MIC was recorded as the lowest concentration of the 
compound that prevented visible growth. 
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In Vitro PK/PD Model 
 
A previously reported in vitro PK/PD model system (19) was used which 
consisted of a two-armed, water jacketed spinner culture flask (1965 series spinner flask, 
Bellco Glass, Vineland, NJ). A prefilter (5μm, Millipore, Billerica, MA) and a filter 
membrane (0.22μm, Millipore, Billerica, MA) were placed in a 25 mm diameter filter 
unit (Pall Corporation, East Hills, NY) and this filter unit which is used to prevent 
leakage of bacteria during the dilution process, was fixed to one end of a custom made 
hollow steel tube. The other end of the steel tube was connected to plastic tubing 
(PharMed tubing, Cole-Parmer, Vernon Hills, IL). This whole filter unit was suspended 
into the media from the top. To ensure homogeneity of the culture and prevent blockage 
of the filter membrane, this flask set up was placed on a magnetic stirrer with a magnetic 
stir bar in the flask. The temperature in the flask was maintained at 37 ⁰C using a 
thermostat controlled water circulator, circulating water to the external jacket of the flask.  
 
One of the side arms of the flask covered with silicone septa was used for dosing 
and repeated sampling while the other side arm was connected to a reservoir containing 
antibiotic free sterile medium through a thin plastic tube (PharMed tubing, Cole-Parmer, 
Vernon Hills, IL). The outlet tubing from the filter unit was connected to a peristaltic 
pump (Masterflex L/S, Cole-Parmer, Vernon Hills, IL) to continuously withdraw the 
medium from the flask at a constant rate. Fresh sterile medium (Middlebrook 7H9, 
Becton Dickinson, Sparks, MD) was pumped into the flask at the same rate.  
 
Figure 4-1 shows the working picture of the in vitro PK/PD system. The solution 
containing the antibiotic Lee1445 was added through the side arm. Lee1445 
concentration in the flask was decreased exponentially according to the equation,  
 
 ܥ ൌ  ܥ଴ · ݁ି௞௧ Eq. 4-1 
 
where C0 is the initial concentration of Lee1445 in the flask, C is the concentration at any 
time t, k is the elimination rate constant and t is the time elapsed since the addition of 
Lee1445. The in vivo half-life (t1/2) of Lee1445 was simulated in the model by changing 
the flow rate according to the equation,  
 
 ܨ ൌ ܸ · ௟௡ଶ௧భ/మ Eq. 4-2 
 
where the elimination rate constant k is equal to F/V, where F is the flow rate of the 
medium and V is the volume of the medium in the flask. The apparatus was sterilized by 
autoclaving between experiments and was kept in a biological safety cabinet during 
operation.  
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A) 
 
 
B) 
 
 
 
Figure 4-1.  In vitro PK/PD system with two working units (Panel A) and its different components (Panel B). 
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Cell Viability Assay 
 
A rapid and sensitive microbial cell viability assay using BacTiter-Glo reagent 
(Promega, Madison, WI) was developed and validated to estimate the number of viable 
bacteria in a given sample of culture based on quantitation of the ATP present. ATP is an 
indicator of metabolically active cells. The homogeneous assay procedure involves 
adding BacTiter-Glo reagent directly to bacterial cells in medium and measuring 
luminescence. It utilizes a proprietary thermo stable luciferase to enable extraction of 
ATP from bacterial cells and to support a stable luminescent signal which can be directly 
measured using a luminometer. An ATP standard curve was established by making serial 
dilutions of ATP and recording the luminescence for each such dilution. For an unknown 
bacterial sample, treated with BacTiter-Glo reagent, ATP content was estimated based on 
the prior established ATP standard curve. A detailed protocol is described in the Promega 
BacTiter-Glo microbial cell viability assay technical bulletin (145).  
 
Fresh media was inoculated with a logarithmically growing culture to obtain 
dilutions of ~103 CFU/mL. This media was allowed to grow in the in vitro PK/PD system 
as well as in a shaker-incubator maintained at 37 ⁰C set to 100 rpm. Aliquots were taken 
on different days until the bacteria reached stationary phase. The number of viable 
bacteria in each sample was determined by plating serial dilutions of the samples on 
antibiotic-free Middlebrook 7H11 agar plates and counting the CFU/mL after incubating 
these plates at 37 ⁰C for 21 days. Simultaneously, ATP content present in each sample 
was measured using the previously described BacTiter-Glo assay. The relationship 
between measured ATP content and the CFU/mL was established using a mathematical 
equation by plotting log CFU/mL versus log ATP (nM). This equation was further used 
to determine the CFU/mL based on the ATP present in the unknown samples.  
 
 
Time-Kill Curves of Lee1445 
 
M. bovis BCG, which is an attenuated derivative of Mycobacterium bovis, a 
virulent tubercle bacillus very closely related to M. tuberculosis (146), was used to 
determine the time-kill curves of Lee1445. M. bovis BCG was grown to early logarithmic 
growth phase in Middlebrook7H9 medium and was then used to inoculate the medium in 
the in vitro model. The final density of the culture in the in vitro system was ~106 
CFU/mL. The medium was drawn from the flask via the combination of a 5 μm and a 
0.22 μm filter at a predetermined flow rate that mimicked the in vivo elimination half-life 
of Lee1445. Fresh sterile medium was pumped into the flask at the same rate through one 
side arm to keep the volume of the medium at the initial level. The addition of Lee1445 
doses was started when the culture had reached the logarithmic growth phase which was 
determined by the optical density of the culture. Lee1445 doses were added daily for 7 
days to simulate in vivo plasma concentration-time profiles in rats. Different total daily 
doses were administered as once daily (QD), twice daily (BID), and thrice daily (TID) 
administration as shown in Table 4-1. Figure 4-2 shows the in vivo concentration-time 
profiles based on rat PK data that were simulated in the in vitro PK/PD system. Although 
an in vivo elimination half-life of 0.43 hr was observed for Lee1445 in rats, due to the 
 62 
 
Table 4-1. Dosing regimens tested in the in vitro PK/PD model. 
 
 
Note: C0: Concentration at time zero 
 
 
  
Dose  
group 
Half-life 
hr 
Dose 
mg/Kg Frequency
Total daily dose 
mg/Kg/day 
Unbound C0 
mg/L 
Control − − − − − 
Treatment 1.26 10 QD 10 15.0 
1.26 50 QD 50 75.1 
1.26 0.2 BID 0.4 0.3 
1.26 1 BID 2 1.5 
1.26 5 BID 10 7.5 
1.26 25 BID 50 37.5 
1.26 3.33 TID 10 5.0 
1.26 16.67 TID 50 25.0 
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A) 
 
 
 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
 
 
 
C) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2. In vivo concentration-time profiles of QD regimens (Panel A), BID 
regimens (Panel B), and TID regimens (Panel C) simulated in the in vitro PK/PD system. 
MIC of Lee1445 against M. bovis BCG was 0.8 µg/mL represented in dotted lines. 
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technical difficulties in operating the pump at higher flow rates limited by the surface 
area of the filter, an adjusted elimination half-life of 1.26 hr was simulated in the in vitro 
model. Approximately 200 μL of the sample was collected at time zero and every day for 
QD, every 12 hr for BID and every 8 hr for TID treatments thereafter until 7 days. The 
number of viable bacteria in each sample was determined using the ATP measurements 
from the sample as a surrogate for estimating CFU/mL using the previously described 
cell viability assay. Simultaneously, serial dilutions of the samples for certain time points 
were plated on antibiotic-free Middlebrook 7H11 agar plates to ensure that the CFU/mL 
estimates obtained using ATP measurements were accurate. The antibacterial activity 
was measured as the reduction in number of viable bacteria, expressed as CFU/mL. No-
drug control was included in the study to assess the extent of killing by Lee1445. 
 
 
Time-Kill Data Analysis 
 
The PK/PD relationship between Lee1445 exposure and microbial kill was 
modeled using a previously described time-kill curve equation (129),  
 
 ௗேௗ௧ ൌ ቂ݇଴ · ቀ1 െ
ே
ே೘ೌೣቁ െ ሺ1 െ ݁
ିఈ·௧ሻ · ቀ ூ೘ೌೣ·஼ூ஼ఱబା ஼ቁቃ · ܰ Eq. 4-3 
 
where N is the M. bovis BCG cell count in CFU/mL, k0 is the bacterial net growth rate 
constant, Nmax is the maximum number of bacteria in the system in CFU/mL, Imax is the 
maximum kill rate, C is the concentration of Lee1445 at time t, and IC50 is the 
concentration at half-maximal kill rate. The logistic growth function, 1-N/Nmax was used 
to describe the limited growth of bacteria in the absence of antibacterial agents. The delay 
rate constant α was incorporated to characterize the initial delay in the killing. All time-
kill data for different dosing regimens were analyzed simultaneously by nonlinear mixed 
effects modeling (NONMEM v.6.2, Icon, Ellicott City, MD). PK parameters were fixed 
in the PK/PD model and set equal to their selected values (V=55 mL, where V is volume 
of the media in the system and half-life, t1/2=1.26 hr). First order conditional estimation 
with interaction in NONMEM which allows interaction between the between-
experimental variability and residual variability was used to analyze the time-kill data 
generated from the in vitro PK/PD system. The data and model predictions were log 
transformed and the random residual variability was modeled using an additive error 
term. The between experiment variability term was incorporated only for the net growth 
rate constant to account for differences in the net growth across different regimens. 
Model performance was analyzed using goodness-of-fit plots, including observed vs. 
predicted, weighted residuals vs. time and weighted residuals vs. predictions plots.  
 
For identification of the most appropriate empirical PK/PD index associated with 
the microbial kill, cell counts on different days were analyzed using an inhibitory sigmoid 
Emax model, as shown in the equation below:  
 
 ܧ ൌ ܧ௠௔௫ – ሺா೘ೌೣିாబሻ·ሺ௉௄௉஽ሻ
ം
ሺ௉௄௉஽ሻംାா஼ఱబം
 Eq. 4-4 
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where, E is the observed M. bovis BCG log CFU/mL, E0 is the BCG cell count in the 
control experiment, Emax is the maximal antimicrobial effect in log CFU/mL, EC50 is the 
value of PK/PD index that produces half-maximal antimicrobial effect and γ is the hill 
coefficient. PKPD is one of the empirical PK/PD indices frequently used in antibiotic 
therapy namely AUC0-24/MIC, Cmax/MIC and T>MIC. The PK/PD index that best 
characterized the effect of Lee1445 on M. bovis was selected based on goodness-of-fit 
criteria and the visual inspection.  
 
 
In Vivo Pharmacokinetic Bridging Study in Mice 
 
Mice weighing approximately 25 g were obtained from Harlan Bioscience 
(Indianapolis, IN). The animals were kept on a 12 hr light/dark cycle with food and water 
available ad libitum. Groups of mice (n = 3 per time point) received an intraperitoneal 
(IP) dose of Lee1445 at a dose level of 20 mg/Kg. Blood samples (~ 250 μL) were 
collected at predetermined time points post-dose until 6 hours. Plasma was separated 
immediately by centrifugation (10,000 rpm for 10 min at 4 ⁰C) and stored at -80 ⁰C until 
analysis. The study protocol was approved by the institutional animal care and use 
committee of the University of Tennessee Health Science Center. Plasma concentration-
time data obtained from this study was analyzed by NONMEM using ADVAN3 
TRANS3 subroutine where a two compartment open model with bolus input and first 
order output was fit to the IP plasma concentration-time data (147). 
 
 
Numerical Simulations 
 
Numerical simulation experiments were performed based on the PK/PD model to 
predict the bactericidal effect of Lee1445 on M. bovis BCG at untested dosing regimens 
in mice, the species used for in vivo infection model of mycobacteria. The murine PK 
parameters of Lee1445 were obtained from the bridging study. Using the PK/PD 
parameters obtained from the experimental time-kill data, and the two compartmental PK 
parameters obtained using the mice concentration-time profile, simulations were 
performed to predict the time-kill effect of Lee1445 for QD, BID and TID regimens in 
mice at doses up to 400 mg/Kg/day. Based on the time-kill effect, optimal doses were 
selected for the in vivo studies performed in M. tuberculosis infected gamma knockout 
(GKO) mice at the Department of Microbiology, Immunology and Pathology, Colorado 
State University. 
 
 
Results and Discussion  
 
 
Cell Viability Assay 
 
The relationship between log CFU/mL and log ATP was found to be linear with a 
regression coefficient (R2) of 0.9853 as shown in Figure 4-3. By measuring the amount of 
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Figure 4-3.  Relationship between cell counts and ATP present in a given sample. 
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ATP present in a test sample, it is possible to estimate the cell viability in terms of 
CFU/mL. In the presence of an antibiotic that is known for its bactericidal action, the 
numbers of bacterial cells decrease over a period of time. This decrease in cell viability 
can be measured by quantifying the amount of ATP present in a sample at any given time 
and extrapolating that using the mathematical relationship to estimate the cell counts in 
CFU/mL. For a slow growing organism such as M. bovis BCG, the time taken for the 
colonies to grow when using the commonly used plating technique is 21 days and it is 
important to minimize such significant amounts of wait time especially during the drug 
development phase to enable faster screening of novel agents. Since this assay helps in 
estimating the cell counts almost instantenously, it gives a significant advantage over the 
already existing techniques for measuring cell counts. However, caution must be taken in 
validating it for a newer class of agents because certain agents tend to significantly 
increase the luminescence and thereby the ATP counts leading to erroneous results. For 
example, in the presence of INH, it was found that although the M. bovis BCG cell counts 
decreased when treated with INH using the plating technique, ATP measurements were 
significantly higher leading to very high cell counts as per the mathematical relationship. 
Hence this assay cannot be used to measure cell viability when cells are treated with INH. 
However, this phenomenon was not observed with spectinamides indicating that this 
assay can be safely used for this class of agents.  
 
 
Time-Kill Curves and PK/PD Parameters 
 
In vitro PK/PD models have many favorable characteristics, such as flexibility, 
adaptability, relatively low cost, good correlation with human and animal data and no 
ethical concerns as compared with animal experiments, which make them excellent 
experimental platforms (81). Especially with anti-TB drugs, the drug-mycobacterial 
interaction can be measured more precisely than in vivo since the influence of the 
immune system is absent in such models (137). The time-kill effect of Lee1445 against 
M. bovis BCG at different dosing regimens is shown in Figure 4-4. Doses 0.4 mg/Kg/day 
and 2 mg/Kg/day administered as BID regimens did not show any bactericidal effect and 
were comparable to untreated control. At much higher doses 10 mg/Kg and 50 
mg/Kg/day administered QD, Lee1445 displayed a static effect where the bacterial cells 
remained in a state of equilibrium with the growth rate balancing out the death rate in the 
flask. The same total daily dose of 10 mg/Kg/day and 50 mg/Kg/day administered as BID 
regimens showed a significant difference in the killing pattern compared to the same total 
daily dose administered as QD regimen. Also comparing the simulated PK concentration-
time profiles shown in Figure 4-2 to the time-kill curves suggests clearly that the time for 
which the concentrations remain above the MIC value (0.8 µg/mL) is nearly doubled 
when administered as BID compared to QD. This result clearly indicates that for better 
efficacy, the concentrations need to remain above MIC for longer periods of time rather 
than the concentrations remaining above a certain threshold value (Cmax) or the exposure 
associated with it (AUC). The time-kill effect of TID regimens did not differ from the 
BID regimens suggesting that a maximum effect was achieved although the 
concentrations remain above MIC for longer periods in TID regimens compared to BID 
regimens. From the dose ranging studies where different doses were administered at a 
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Figure 4-4.  Time-kill effect of Lee1445 against M. bovis BCG with observed log 
CFU/mL plotted against time for different dosing regimens. 
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fixed interval, it is evident that higher doses produced better time-kill effect. For example 
in BID regimens, doses from 0.4 mg/Kg/day and up to 50 mg/Kg/day showed a 
significant difference in the bactericidal effect suggesting that there is clearly a dose-
dependent effect.  
 
A semi-mechanistic PK/PD model incorporating a logistic function for growth of 
mycobacteria in the absence of drug and an inhibitory sigmoidal Emax model with a delay 
function for the time-kill effect of the drug was fit to the data obtained from in vitro 
PK/PD studies. The maximum growth rate constant (K0) was estimated to be 0.0274 hr-1 
which corresponds to a maximum doubling time of 25.3 hr. The commonly observed in 
vitro doubling times when working with M. bovis BCG are in the range of 20 -24 hr (148) 
suggesting that the observed doubling time is comparable to the published range. A 
maximum bacterial kill rate (Imax) was calculated as 0.0566 hr-1, suggesting that in the 
absence of growth, it takes nearly 12.2 hours for the bacterial counts to be halved. The 
concentration of the drug required to produce half-maximum inhibition (IC50) was 
calculated as 2.62 mg/L. Since there was a delay in the commencement of the actual 
killing effect, a delay function was employed in the equation. The delay rate constant for 
the initial kill was found to be 0.0245 hr-1, suggesting the half-life of the delay in the 
initial kill equivalent to 28.3 hr. The results of this analysis are shown in Table 4-2 and 
the model predicted profiles for various dosage regimens are shown in Figure 4-5.  
 
Examination of the relationship between empirical PK/PD indices and microbial 
kill for day 6 of the treatment revealed that the PK/PD index T>MIC was able to describe 
the Lee1445 mediated microbial kill (Figure 4-6). Similar results were observed for days 
3, 4, and 5 data (results not shown). AUC0-24/MIC and Cmax/MIC did not show any 
relevance to the microbial kill on any given day indicating that it is a time dependent 
rather than a concentration dependent antibacterial kill. The parameter estimates from the 
empirical PK/PD analysis are listed in Table 4-3. This analysis suggests that the longer 
the free drug concentrations remain above MIC the better the microbial kill. Clinically, 
this can be achieved by administering the drug more frequently or by administration of 
higher doses so that the free drug concentrations remain above MIC for longer periods in 
spite of the short half-life of the drug as in the case of Lee1445.  
 
 
In Vivo Pharmacokinetic Bridging Study in Mice 
 
The efficacy studies in a tuberculosis infection model were carried out in gamma 
knockout (GKO) mice. Since the pharmacokinetic profile varies across species, it is 
important to understand the differences in the pharmacokinetic parameters between rats 
and mice in order to design a rational dosing regimen. To characterize the PK properties 
in mice, a bridging study was performed where Lee1445 was administered intra-
peritoneally to healthy mice at a dose of 20 mg/Kg. Figure 4-7 shows the 
pharmacokinetic profile of Lee1445 in mice. A two compartmental model was fitted to 
the data and the pharmacokinetic parameters obtained are shown in Table 4-4. The 
clearance was higher in mice and the t1/2α was relatively shorter in mice compared to rats 
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Table 4-2. In vitro PK/PD parameter estimates of Lee1445. 
 
Parameter Units Estimate (RSE) BEV (%CV) 
K0 hr-1 0.0274 (24.5) 48.4 
IC50 mg/L 2.62 (90.8) 
Imax hr-1 0.0566 (30.9) 
α hr-1 0.0245 (14.3) 
RV %CV 22 (13.8) 
 
Notes: RSE: Relative standard error  
BEV: Between experiment variability 
 K0: maximum growth rate constant in the absence of drug 
IC50 : concentration needed to produce half-maximal effect 
Imax: maximum bacterial kill rate 
α: delay rate constant  
RV: Residual variability 
CV: Coefficient of variation 
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Figure 4-5. Model predicted profiles for various dosage regimens. LCFU is observed 
log CFU/mL data from in vitro PK/PD model, IPRE is individual predicted log CFU/mL 
for each dosing regimen, PRE is predicted log CFU/mL from the mean parameters of the 
mathematical model.   
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A)       B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
C) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6. PK/PD indices and their relationship to the microbial kill on day 6. No 
correlation is seen between microbial kill versus unbound AUC0-24/MIC (Panel A) or 
versus unbound Cmax/MIC (Panel B). An inhibitory sigmoidal relationship can be seen 
between day 6 microbial kill and T>MIC (Panel C).  
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Table 4-3. Parameters for empirical PK/PD index T>MIC based on day 6 data. 
 
Parameter Units Estimate %CV 
Emax log CFU/mL 8.09 10.4 
EC50 hr 7.38 18.5 
E0 log CFU/mL 3.34 30.5 
γ 5.18 93.9 
 
Notes: CV: Coefficient of variation 
Emax: Initial M. bovis BCG count in log CFU/mL  
E0: M. bovis BCG count at the end of experiment in log CFU/mL  
EC50: T>MIC value that produces half-maximal antimicrobial effect  
γ: Hill coefficient  
 
 
 
 
 
  
 74 
 
 
 
 
Figure 4-7. Pharmacokinetic profile of Lee1445 in rats following 20 mg/Kg IP 
injection. Circles indicate observed concentrations and triangles indicate model predicted 
concentrations. 
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Table 4-4. Lee1445 in vivo pharmacokinetic differences between rat and mouse. 
 
Parameter Units Rat Mouse 
CL L/hr/Kg 0.56 0.73 
Vss L/Kg 1.03 1.26 
t1/2α hr 0.32 0.25 
t1/2β hr 20.9 21.0 
 
Notes: CL: Total body clearance 
 Vss: Volume of distribution at steady state 
 t1/2α: Half-life associated with the macro rate constant α 
 t1/2β: Half-life associated with the macro rate constant β 
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suggesting that higher doses are needed in comparison to rats to achieve a given target 
concentration and systemic exposure. 
 
 
Numerical Simulations 
 
Utilizing the pharmacokinetic parameters from the mice PK bridging study and 
the pharmacodynamic parameters from the in vitro time-kill experiments, numerical 
simulations were performed in order to predict the bactericidal effect of Lee1445 on M. 
bovis BCG at untested dosing regimens. Since the clearance of Lee1445 was higher in 
mice compared to rats, higher doses were chosen for simulations in comparison to the 
ones tested in the in vitro PK/PD system. Figures 4-8, 4-9 and 4-10 show the predicted 
efficacy for QD, BID and TID dosing scenarios respectively. A dose response 
relationship was clearly evident in each of these dose escalation scenarios where higher 
doses predicted better efficacy. Figure 4-11 shows predicted efficacy profiles for a total 
daily dose of 200 mg/Kg/day fractionated as QD, BID and TID regimens. Even though 
the same total daily dose was administered, BID and TID regimens showed better 
efficacy compared to QD regimen. Since TID is practically cumbersome, the BID 
regimen was chosen over TID regimen. Hence from these simulation studies, 200 
mg/Kg/day administered BID was chosen as the optimal dose to test in the GKO mouse 
model. In order to evaluate the upper end of the dose response relationship in the GKO 
mouse model, we also recommended a higher dose of 400 mg/Kg/day BID to be 
incorporated in the in vivo efficacy studies.  
 
In one of the preliminary in vivo efficacy studies of Lee1329 performed in the 
GKO mice infected with MTB performed at Colorado State University by our 
collaborators, an arbitrary dose of 200 mg/Kg QD was chosen. This dose was 
administered as a subcutaneous injection for nine days and CFU/mL were evaluated in 
the lungs of the animals at the end of nine days. Results from this study are presented in 
Figure 4-12. Lee1329 showed approximately one log reduction in bacterial counts in the 
lungs compared to an untreated control. Streptomycin administered as 200 mg/Kg via the 
subcutaneous route served as a positive control. Lee1329 showed promising 
antituberculosis activity very similar to that of streptomycin in these studies. However, 
the dose selection criterion in these studies was arbitrary and not based on a rational 
PK/PD modeling approach. There was no evidence that the dose selected would provide 
the optimal efficacy in these animals.  
 
The predictions from the simulations thus suggested that total daily dose of 200 
mg/Kg/day and 400 mg/Kg/day administered BID would be optimal and result in 
approximately 2 and 3 log reduction in bacterial counts, respectively, after seven days of 
therapy. Therefore these Lee1445 doses selected from the numerical simulations were 
evaluated in the interferon-γ knockout mice infected with MTB. Results from this study 
are presented in Figure 4-13. These results indicate a dose-dependent in vivo efficacy as 
predicted from the numerical simulations. There was an improved reduction (from 1 log 
CFU/mL to 1.6 log CFU/mL) in bacterial counts in the lungs due to dose fractionation as 
evidenced from the in vitro PK/PD study and the numerical simulations. Although the 
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Figure 4-8. Numerical simulations for once daily dosing regimens of Lee1445 in 
mice. 
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Figure 4-9. Numerical simulations for twice daily dosing regimens of Lee1445 in 
mice. 
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Figure 4-10. Numerical simulations for thrice daily dosing regimens of Lee1445 in 
mice. 
  
 80 
 
 
 
 
Figure 4-11. Simulated efficacy profiles of 200 mg/Kg/day administered as QD, BID 
and TID regimens. 
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Figure 4-12. Preliminary in vivo efficacy study of Lee1329 in the GKO mouse model 
where the dose selection criterion was arbitrary. 
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Figure 4-13. In vivo efficacy study of Lee1445 in the GKO mouse model where the 
dose selection criterion was based on PK/PD modeling approach. 
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simulations over predicted the efficacy, they did predict a general trend that was seen in 
the dose-response relationship in the in vivo efficacy studies. 
 
 
Conclusion 
 
In conclusion, we developed and validated a faster way to determine the counts of 
colony forming units of a slow growing organism, M. bovis BCG and determined the 
time-kill profiles for dosing regimens of Lee1445 against this organism. A semi-
mechanistic PK/PD model developed was able to describe the effect of Lee1445 on the 
growth and survival of M. bovis BCG. Model-based numerical simulations suggested that 
a twice daily dosing regimen could produce similar antibacterial effects in the GKO mice 
as observed in the in vitro kill curve analysis. This assumption was supported by the 
results obtained in the in vivo efficacy studies. These findings support the hypothesis that 
by using a rational PK/PD approach and simulating the in vivo pharmacokinetic profile at 
different dosing regimens in an in vitro PK/PD system facilitates characterizing the dose-
response relationship of novel anti-infectives against TB and selecting an optimal dosing 
regimen for maximal in vivo efficacy in animal models infected with TB. 
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CHAPTER 5. SUMMARY OF DISSERTATION RESEARCH 
 
 
With extensive support from several organizations, tuberculosis drug research has 
been attracting renewed interest after several decades of neglect. Although no new major 
classes of drugs have been approved for the treatment of TB since the introduction of the 
rifamycins into the market in 1971 (143), new and promising drug candidates have been 
in the discovery to late drug development phases over the past 10 years that provided 
hope to improve the treatment and control this dreadful threat. However, the situation is 
critical with increasing incidence of TB infections and growing numbers of patients with 
multidrug resistant TB and extensively drug resistant TB. Currently used treatment 
strategies involve multiple drugs with treatment periods ranging from six to nine months 
and especially patients with MDR-TB undergo treatment up to two years with more toxic 
and expensive drugs with poor patient compliance. Hence there is a definite need for 
more effective and better tolerated antituberculosis agents to go into optimized, less 
complicated and shorter dosage regimens. 
 
In an effort to develop more potent drugs for the treatment of TB, a novel class of 
antituberculosis agents called spectinamides, with promising in vitro activity against 
MTB, has been recently characterized by our group. One of the main objectives of this 
work was to characterize the biopharmaceutic and pharmacokinetic properties of some of 
the active spectinamides and develop a rational screening paradigm which will help in the 
early drug development process. I hypothesized that designing a screening paradigm with 
ADME and drug uptake assays into mycobacterium as well as macrophages would 
facilitate the identification and characterization of lead compounds specific for 
antituberculosis therapy. To address this hypothesis, I utilized a series of existing in vivo 
and in vitro assays such as plasma protein binding, microsomal metabolic stability and in 
vivo pharmacokinetics, and developed novel drug uptake assays into M. bovis BCG and 
J774 murine macrophage to identify and characterize lead molecules from this novel 
spectinamide series of antituberculosis agents.  
 
From the results of these assays, we found that spectinamides exhibit low to 
intermediate plasma protein binding and are metabolically stable with the exception of 
Lee1540. Following intravenous administration, spectinamides are relatively widely 
distributed (0.36 to 1.15 L/Kg) with short half-lives (0.43 to 0.62 hr) and the mean 
systemic clearance ranging between 0.36 and 0.89 L/hr/Kg with a significant fraction of 
drug eliminated unchanged in urine (0.46 to 1.0). Spectinamides except for Lee1540 
exhibit a renal excretion ratio greater than 1 indicating filtration and active secretion as 
the net renal elimination process. In the uptake experiments, spectinamides exhibited 3-4 
times higher uptake into murine macrophages compared to streptomycin and showed 
nearly four times higher uptake into M. bovis BCG compared to spectinomycin, which 
may in part explain their increased activity compared to spectinomycin. Thus, we 
characterized the pharmacokinetic properties of key compounds in the spectinamide 
series and developed a screening paradigm that could be used for further optimization of 
leads specifically against MTB.  
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Another important objective was to investigate the time course of bacterial kill of 
Lee1445 using an in vitro PK/PD system in order to identify the optimal dosing regimen 
as well as to identify the empirical PK/PD index which correlates with the therapeutic 
outcome. I hypothesized that simulating the in vivo pharmacokinetic profile at different 
dosing regimens in an in vitro PK/PD system helps in charactering the dose-response 
relationship which further facilitates rational dose selection of Lee1445 for the in vivo 
efficacy study in animal models infected with TB. To achieve this objective, PK 
concentration-time profiles were simulated on the basis of the in vivo clearance of rats 
and the time-kill effect of different daily doses of Lee1445 were studied on the growing 
M. bovis BCG present in the PK/PD system. A novel and rapid method to quantify the 
bacterial counts based on the ATP measurements was developed. A mathematical model 
was fit to the time-kill data and in vitro PK/PD parameters were determined. Since the in 
vivo efficacy model of tuberculosis infection was the gamma knock-out (GKO) mouse, a 
PK bridging study was performed in mice. Simulations for various dosing regimens were 
performed using the obtained mouse PK parameters and the in vitro PK/PD parameters, 
which were incorporated into a combined PK/PD model to predict the efficacy in terms 
of reduction of bacterial counts. Based on the results of the simulations, an optimal dose 
was chosen for the in vivo efficacy study. 
 
In vitro PK/PD studies showed that QD was marginally effective and the same 
total daily dose administered BID showed a marked reduction in mycobacterial counts. 
The parameters obtained from the semi-mechanistic PK/PD model correlated well with 
the physiological and microbiological parameters. The in vitro doubling time of M. bovis 
BCG was found to be 25.3 hr and the half-life of the delay in the initial kill was 
approximately 28 hr. The concentration of the drug required to produce half-maximum 
inhibition (IC50) was calculated as 2.62 mg/L. The PK/PD index T>MIC was able to 
describe the Lee1445 mediated microbial kill, indicating that it is a time dependent rather 
than a concentration dependent antibacterial kill. This analysis indicated that the longer 
the free drug concentrations remain above MIC the better the microbial kill would be. 
Since Lee1445 has a short half-life of 0.43 hr, this analysis indicates that by 
administering the drug more frequently or by administration of higher doses, the free 
drug concentrations would remain above MIC for longer periods and thereby lead to 
improved efficacy.  
 
A total daily dose of 200 mg/Kg/day and 400 mg/Kg/day of Lee1445 
administered BID was chosen from simulations based on the parameters obtained from 
the mouse PK bridging study and the in vitro PK/PD model. Simulations predicted that 
these regimens would result in approximately 2 and 3 log reduction in bacterial counts 
respectively after seven days of therapy. Lee1445 doses selected from the numerical 
simulations were evaluated in the GKO mice infected with MTB and a dose-dependent in 
vivo efficacy as predicted from the numerical simulations was evident. Dose fractionation 
lead to an improved reduction in bacterial counts in the lungs of GKO mice from 1 to 1.6 
log CFU/mL as predicted from the numerical simulations. Although the simulations over 
predicted the efficacy, they did predict a general trend that was seen in the dose-response 
relationship in the in vivo efficacy studies. These findings support the hypothesis that by 
using a rational PK/PD approach and simulating the in vivo pharmacokinetic profile at 
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different dosing regimens in an in vitro PK/PD system facilitates in characterizing the 
dose-response relationship and dose selection for the in vivo efficacy study in animals 
infected with TB. 
 
In summary, we have successfully developed an iterative PK/PD guided process 
for lead optimization and characterization of spectinamides that uses a set of 
biopharmaceutic, pharmacokinetic and pharmacodynamic evaluations designed to 
identify the compounds suitable for further development. The utilization of PK/PD 
modeling and simulation techniques facilitated in characterizing the time course of the 
effect intensity of these antibiotics and resulted in an evidence-based dosage selection 
criterion that leads to a scientifically driven drug development process. The results of this 
study serve as an example for the optimization of lead compounds against tuberculosis. 
The general approach described in this dissertation, however, can also be applied for lead 
optimization of other chemical classes not only for treating tuberculosis but also for other 
bacterial infections. 
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